Treatment or prevention of HIV infection

JP2023550079A5Pending Publication Date: 2024-11-26JANSSEN SCI IRELAND UC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023529034
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-17
Filing Date
2021-11-17
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Current HIV treatment and prevention methods require frequent administration, leading to patient noncompliance and potential resistance, and existing injectable forms cause injection site reactions and visibility of HIV status.

Method used

Administering rilpivirine in the form of microparticles or nanoparticles in suspension combined with hyaluronidase via intramuscular or subcutaneous injection at intervals of 3 months to 2 years, which improves tolerability and maintains sustained release.

Benefits of technology

This method reduces the frequency of administration, enhances patient compliance, and minimizes injection site reactions while maintaining effective plasma levels of rilpivirine, making it less visible and more tolerable.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the treatment or prevention of HIV infection using rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension in combination with hyaluronidase. The present invention also relates to rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to the treatment or prevention of HIV infection using rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension in combination with hyaluronidase. The present invention also relates to rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension. [Background technology]

[0002] Treatment of human immunodeficiency virus (HIV) infection, known as the cause of acquired immune deficiency syndrome (AIDS), remains a major medical challenge. HIV can escape immunological suppression, adapt to various cell types and growth conditions, and develop resistance to anti-HIV drugs, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), HIV protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and HIV fusion inhibitors.

[0003] Although effective in suppressing HIV infection, each of these drugs faces the emergence of resistance variants when used alone. This has led to the introduction of combination therapies of several anti-HIV agents, usually with different activity profiles. In particular, the introduction of "HAART" (highly active antiretroviral therapy) has brought about significant improvements in anti-HIV therapy and led to a dramatic reduction in HIV-related morbidity and mortality. Current guidelines for antiretroviral therapy recommend double or triple combination treatment regimens. However, none of the currently available drug therapies can completely eradicate HIV infection. Even HAART can face the emergence of resistance, often due to nonadherence and non-persistence to antiretroviral therapy. In these cases, HAART can be reactivated by replacing one of its components with another class of drug. When applied correctly, combination HAART treatment can suppress the virus for many years, even decades, to a level that no longer triggers the AIDS epidemic.

[0004] Because HIV infection cannot currently be completely eradicated, people infected with HIV have the potential risk of infecting others. People may live for years without experiencing any effects of the infection and may therefore be unaware of the risk of further transmitting the virus to others. Therefore, prevention of HIV infection is extremely important. Prevention currently focuses on avoiding transmission through sexual contact through the use of condoms, especially in at-risk populations, carefully monitoring blood samples for the presence of HIV, and avoiding contact with the blood of potentially infected subjects.

[0005] Despite these measures, there is always a pressing risk that individuals will come into contact with an HIV-infected person and become infected. This is particularly true for those who provide medical care to infected or at-risk patients, such as doctors, nurses, or dentists. Another group of individuals at risk are breastfed infants whose mothers are infected or at risk of infection, especially in developing countries where alternatives to breastfeeding are less clear.

[0006] Currently available oral therapies require at least one daily dose. Therefore, people living with HIV are reminded daily of their HIV-positive status, and daily dosing may reveal their HIV-positive test status. Daily dosing requires the storage and transportation of multiple or large amounts of pills, and there remains a risk that patients will not adhere to the prescribed dosing regimen by forgetting to take their daily dose. In addition to reducing the effectiveness of treatment, this also leads to the development of viral resistance.

[0007] One class of HIV drugs often used in HAART is NNRTIs. Rilpivirine is an antiretroviral drug of the NNRTI class used to treat HIV infection. Rilpivirine is a second-generation NNRTI with greater efficacy and a reduced side effect profile compared to older NNRTIs. Rilpivirine activity is mediated by noncompetitive inhibition of HIV-1 reverse transcriptase.

[0008] Rilpivirine not only exhibits significant activity against wild-type HIV, but also against many of its mutated variants. Rilpivirine, its pharmacological activity, and several procedures for its preparation are described in WO 03 / 16306.

[0009] Rilpivirine is approved for the treatment of HIV infection and is commercially available as a single tablet containing 25 mg of rilpivirine base equivalent per tablet for once-daily oral administration (EDURANT®), and as a single-tablet regimen for once-daily oral administration (COMPLERA®, ODEFSEY®, JULUCA®).

[0010] WO2007147882 discloses intramuscular or subcutaneous injection of a therapeutically effective amount of rilpivirine in the form of microparticles or nanoparticles having a surface modifier adsorbed to the surface thereof, and a pharmaceutically acceptable aqueous carrier in which the rilpivirine active ingredient is suspended.Products containing rilpivirine for the treatment of HIV infection by monthly or bimonthly injection are currently under development.

[0011] Rilpivirine injectable extended-release suspension for administration in combination with cabotegravir injectable extended-release suspension is approved in Canada as CABENUVA®, and the EMA has recommended granting marketing authorization for rilpivirine injectable extended-release suspension (REKAMBYS®) in Europe. These are the first antiretroviral medicines available in a long-acting injectable formulation for administration at intervals of more than one day.

[0012] For drugs administered by subcutaneous or intramuscular injection, such as rilpivirine, patient tolerance is an additional concern, especially when larger doses are injected. For example, administration by subcutaneous or intramuscular injection can result in irritation, inflammation, swelling, acute pain, and / or redness and bruising at the injection site during and after injection (injection site reaction). Subcutaneous and intramuscular injections can also be associated with the appearance of bumps on the skin surface at the injection site, especially when larger doses are injected. Such effects are generally exaggerated by high injection volumes. Such bumps may reveal that the subject has received a large injection volume and therefore may reveal the subject's HIV-positive status. Summary of the Invention [Problem to be solved by the invention]

[0013] Thus, in addition to the need to provide an effective method for preventing HIV transmission or treating HIV infection that requires infrequent administration, i.e., administration only once every few months or more, there is also a need for this method to be well tolerated, thus improving patient compliance, and there is also a need for this method to be invisible to the outside world. [Means for solving the problem]

[0014] In a first aspect, a method for treating or preventing HIV infection in a subject in need thereof is provided, the method comprising administering to the subject by intramuscular or subcutaneous injection a therapeutically effective amount of rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension, wherein the rilpivirine or pharmaceutically acceptable salt thereof is administered in combination with hyaluronidase administered by intramuscular or subcutaneous injection, and wherein the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at time intervals of from about 3 months to about 2 years.

[0015] In a second aspect, there is provided rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use in treating or preventing HIV infection in a subject, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension, and the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered to the subject by intramuscular or subcutaneous injection, and the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

[0016] In a third aspect, a product is provided containing rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase as a combined preparation for simultaneous or sequential use in the treatment or prevention of HIV infection by intramuscular or subcutaneous injection, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension, and the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

[0017] In a fourth aspect, there is provided a kit of parts comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for simultaneous or sequential use in the treatment or prevention of HIV infection by intramuscular or subcutaneous injection, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension, and the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

[0018] In a fifth aspect, there is provided rilpivirine or a pharmaceutically acceptable salt thereof in the form of a suspension of microparticles or nanoparticles for use in the treatment or prevention of HIV infection by intramuscular or subcutaneous injection, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is administered in combination with hyaluronidase administered by intramuscular or subcutaneous injection, and the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered intermittently at time intervals of from about 3 months to about 2 years.

[0019] In a sixth aspect, there is provided a use of rilpivirine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing HIV infection in a subject, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension and is administered in combination with hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered to the subject by intramuscular or subcutaneous injection, and the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

[0020] In a seventh aspect, there is provided a combination comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension.

[0021] In an eighth aspect, a kit of parts is provided comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension.

[0022] Administration of rilpivirine in combination with hyaluronidase via subcutaneous or intramuscular injection improves patient tolerance compared to subcutaneous or intramuscular administration of rilpivirine alone, especially when large doses are injected. Hyaluronidase may facilitate more rapid administration of rilpivirine because it can reduce the resistance of the tissue into which the rilpivirine suspension is delivered. Hyaluronidase may reduce leakage of rilpivirine from the injection site by reducing tissue backpressure. Hyaluronidase may also allow for the delivery of larger doses in patients with less subcutaneous tissue (or a lower body mass index). Hyaluronidase may allow for the use of shorter needles.

[0023] Furthermore, it has surprisingly been found that the sustained, sustained, or prolonged release of rilpivirine into the plasma achieved by intramuscular or subcutaneous injection of a suspension of rilpivirine microparticles or nanoparticles can be maintained when rilpivirine is administered with a hyaluronidase as defined herein. As discussed in more detail below in the section entitled "Hyaluronidase," hyaluronidase is used to increase the dispersion and absorption of injected active pharmaceutical ingredients. In light of this, it is surprising that the inventors have demonstrated that administering hyaluronidase with rilpivirine maintains the extended, sustained, or prolonged release of rilpivirine into the bloodstream.

[0024] In a ninth aspect, there is provided rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in suspension, the microparticles or nanoparticles having a D of about 1 μm to about 10 μm. v It has 90.

[0025] In a tenth aspect, there is provided a pharmaceutical composition comprising rilpivirine or a pharmaceutically acceptable salt thereof as defined in the ninth aspect.

[0026] In an eleventh aspect, there is provided rilpivirine, or a pharmaceutically acceptable salt thereof, as defined in the ninth aspect, for use in the treatment or prevention of HIV infection in a subject.

[0027] In a twelfth aspect, there is provided a method for treating or preventing HIV infection in a subject, the method comprising administering to the subject rilpivirine or a pharmaceutically acceptable salt thereof according to the ninth aspect of the invention in the form of microparticles or nanoparticles in a suspension, wherein the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v It has 90.

[0028] In a thirteenth aspect, there is provided the use of rilpivirine or a pharmaceutically acceptable salt thereof according to the ninth aspect of the invention, i.e., rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in suspension, for the manufacture of a medicament for treating or preventing HIV infection in a subject, wherein the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v 90, the use is provided.

[0029] Surprisingly, D of about 1 μm to about 10 μm v Rilpivirine in the form of microparticles or nanoparticles with a lower D v It has been found that the dissolution profile of rilpivirine is reduced, i.e., flattened, compared to rilpivirine in the form of microparticles or nanoparticles having a D of about 1 μm to about 10 μm. v Administration of rilpivirine in the form of microparticles or nanoparticles having a D of about 1 μm to about 10 μm modulates rilpivirine exposure and flattens the pharmacokinetic curve, i.e., reduces the Cmax of the pharmacokinetic curve, while maintaining sustained or prolonged release of rilpivirine into the plasma. v Administration of rilpivirine in the form of microparticles or nanoparticles with a lower Dv Multiple doses may result in improved peak-to-trough ratios compared to administration of rilpivirine in the form of microparticles or nanoparticles having a 90.degree. [Brief explanation of the drawings]

[0030] The present invention will now be described, by way of example only, with reference to the accompanying drawings. [Figure 1] FIG. 1 shows the mean plasma concentrations over time following administration of rilpivirine nanosuspension according to the present invention and hyaluronidase, and rilpivirine nanosuspension alone. [Figure 2] FIG. 1 shows mean plasma concentrations over 6 months following administration of a rilpivirine suspension and hyaluronidase according to the present invention, and rilpivirine suspension alone. [Figure 3] FIG. 1 shows dissolution studies using rilpivirine suspensions with different particle sizes. [Figure 4] FIG. 10 shows further dissolution studies using rilpivirine suspensions of various particle sizes.

[0031] These figures are further explained in the "Examples" section. DETAILED DESCRIPTION OF THE INVENTION

[0032] This application is divided into several sections to facilitate readability. However, this does not mean that each section should be read in isolation. To the contrary, unless otherwise specified, each section should be read with cross-reference to the other sections, i.e., with the entire application taken as a whole. No artificial separation of embodiments is intended unless explicitly stated.

[0033] Thus, all of the embodiments described herein with respect to the first aspect of the invention apply equally to the second to eighth aspects described herein, i.e., are also disclosed in relation to / in combination with aspects 2 to 8. Also, all of the embodiments described herein with respect to the ninth aspect of the invention apply equally to the tenth to thirteenth aspects of the invention, i.e., are also disclosed in relation to / in combination with aspects 10 to thirteenth aspects of the invention.

[0034] Detailed Description of the Invention Rilpivirine Rilpivirine (4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile; TMC278) has the following structural formula:

[0035] [ka]

[0036] "Rilpivirine" means rilpivirine having the structural formula shown above, i.e., the free base form.

[0037] The rilpivirine or pharmaceutically acceptable salt thereof used in the first and ninth aspects of the present invention is in the form of microparticles or nanoparticles in suspension, i.e., microparticles or nanoparticles of rilpivirine or a pharmaceutically acceptable salt thereof in suspension, in particular microparticles or nanoparticles of rilpivirine or a pharmaceutically acceptable salt thereof suspended in a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable aqueous carrier.

[0038] A pharmaceutically acceptable salt of rilpivirine means that the counter ion is pharmaceutically acceptable. Pharmaceutically acceptable salts include therapeutically active non-toxic acid addition salts that can form rilpivirine. These salts can be easily obtained by treating rilpivirine with a suitable acid, such as an inorganic acid, for example, a hydrohalic acid such as hydrochloric acid or hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid; or an organic acid, for example, acetic acid, propanoic acid, hydroxyacetic acid, 2-hydroxypropanoic acid, 2-oxopropanoic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, 2-hydroxy-1,2,3-propanetricarboxylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, cyclohexanesulfamic acid, 2-hydroxybenzoic acid, 4-amino-2-hydroxybenzoic acid, etc.

[0039] In preferred embodiments of the first and ninth aspects of the present invention, the rilpivirine or a pharmaceutically acceptable salt thereof used in the present invention is rilpivirine, ie, rilpivirine in its free base form.

[0040] Those skilled in the art will appreciate that the size of the microparticles or nanoparticles in the first aspect of the invention should be below a maximum size above which administration by subcutaneous or intramuscular injection becomes impaired or no longer possible, the maximum size depending, for example, on limitations imposed by the diameter of the needle, or by the body's adverse reaction to large particles, or both.

[0041] In a preferred embodiment of the first aspect of the present invention, the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of nanoparticles.

[0042] In one embodiment of the first aspect of the invention, the microparticles or nanoparticles described herein have an average effective particle size of less than about 20 μm. In one embodiment of the first aspect of the invention, the microparticles or nanoparticles have an average effective particle size of less than about 10 μm. In one embodiment of the first aspect of the invention, the microparticles or nanoparticles have an average effective particle size of less than about 5 μm. In one embodiment of the first aspect of the invention, the microparticles or nanoparticles have an average effective particle size of less than about 1 μm. In one embodiment of the first aspect of the invention, the microparticles or nanoparticles have an average effective particle size of less than about 500 nm.

[0043] In another embodiment of the first aspect of the present invention, the microparticles or nanoparticles described herein have an average effective particle size of about 25 nm to about 20 μm. In another embodiment of the first aspect of the present invention, the microparticles or nanoparticles have an average effective particle size of about 25 nm to about 10 μm (e.g., about 200 nm to about 10 μm). In another embodiment of the first aspect of the present invention, the microparticles or nanoparticles have an average effective particle size of about 25 nm to about 5 μm (e.g., about 200 nm to about 5 μm). In another embodiment of the first aspect of the present invention, the microparticles or nanoparticles have an average effective particle size of about 25 nm to about 1 μm. In another embodiment of the first aspect of the present invention, the microparticles or nanoparticles have an average effective particle size of about 25 nm to about 500 nm.

[0044] In a preferred embodiment of the first aspect of the invention, the microparticles or nanoparticles described herein have an average effective particle size of about 100 nm to about 300 nm. In another preferred embodiment of the first aspect of the invention, the microparticles or nanoparticles have an average effective particle size of about 150 nm to about 250 nm. In a particularly preferred embodiment of the first aspect of the invention, the microparticles or nanoparticles have an average effective particle size of about 180 nm to about 220 nm, e.g., about 200 nm.

[0045] In alternative embodiments of the first and ninth aspects of the present invention, the microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm. In one embodiment of the first and ninth aspects of the present invention, the microparticles or nanoparticles have an average effective particle size of about 0.4 μm to about 3 μm. In one embodiment of the first and ninth aspects of the present invention, the microparticles or nanoparticles have an average effective particle size of about 0.6 μm to about 3 μm. In one embodiment of the first and ninth aspects of the present invention, the microparticles or nanoparticles have an average effective particle size of about 0.7 μm to about 3 μm. In one embodiment of the first and ninth aspects of the present invention, the microparticles or nanoparticles have an average effective particle size of about 0.8 μm to about 3 μm. In one embodiment of the first and ninth aspects of the present invention, the microparticles or nanoparticles have an average effective particle size of about 0.9 μm to about 3 μm. In one embodiment of the first and ninth aspects of the present invention, the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm. In one embodiment of the first and ninth aspects of the invention, the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. In one embodiment of the first and ninth aspects of the invention, the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2 μm. In one embodiment of the first and ninth aspects of the invention, the microparticles or nanoparticles have an average effective particle size of 0.3 μm, 0.4 μm, 0.5 μm, 0.6 μm, 0.7 μm, 0.8 μm, 0.9 μm, 1 μm, 1.1 μm, 1.2 μm, 1.3 μm, 1.4 μm, 1.5 μm, 1.6 μm, 1.7 μm, 1.8 μm, 1.9 μm, 2 μm, 2.1 μm, 2.2 μm, 2.3 μm, 2.4 μm, 2.5 μm, 2.6 μm, 2.7 μm, 2.8 μm, 2.9 μm, or 3 μm, or any subrange or single value between 0.2 μm and 3 μm.

[0046] In one embodiment of the first and ninth aspects of the invention, the microparticles or nanoparticles have an average effective particle size of about 1.5 μm to about 3 μm. In one embodiment of the first and ninth aspects of the invention, the microparticles or nanoparticles have an average effective particle size of about 2 μm to about 3 μm, e.g., about 2.5 μm or about 2.7 μm.

[0047] As used herein, the term "average effective particle size" refers to the volume-based median particle size (D v 50), i.e., refers to the diameter below which 50% by volume of the particle population is found.

[0048] In an alternative embodiment of the first aspect of the invention, the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v It has 90.

[0049] The microparticles or nanoparticles of the ninth aspect of the present invention have a D of about 1 μm to about 10 μm. v It has 90.

[0050] In one embodiment of the first and ninth aspects of the invention, the microparticles or nanoparticles have a D of about 1 μm to about 7 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 1.5 μm to about 7 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 2 μm to about 6 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 2.5 μm to about 6.5 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 2.5 μm to about 4 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 3 μm to about 7 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 4 μm to about 7 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v In one embodiment, the microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. vIn one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 4.5 μm to about 6.5 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a D of about 5 μm to about 6 μm, for example about 5.5 μm. v In one embodiment of the first and ninth aspects, the microparticles or nanoparticles have a diameter of 2 μm, 2.1 μm, 2.2 μm, 2.3 μm, 2.4 μm, 2.5 μm, 2.6 μm, 2.7 μm, 2.8 μm, 2.9 μm, 3 μm, 3.1 μm, 3.2 μm, 3.3 μm, 3.4 μm, 3.5 μm, 3.6 μm, 3.7 μm, 3.8 μm, 3.9 μm, 4 μm, 4.1 μm, 4.2 μm, 4.3 μm, 4.4 μm, ... 0.5 μm, 4.6 μm, 4.7 μm, 4.8 μm, 4.9 μm, 5 μm, 5.1 μm, 5.2 μm, 5.3 μm, 5.4 μm, 5.5 μm, 5.6 μm, 5.7 μm, 5.8 μm, 5.9 μm, 6 μm, 6.1 μm, 6.2 μm, 6.3 μm, 6.4 μm, 6.5 μm, 6.6 μm, 6.7 μm, 6.8 μm, 6.9 μm, or 7 μm, or any subrange or single value of D between 2 μm and 7 μm v It has 90.

[0051] The term “D v "90", as used herein, refers to the diameter below which 90% by volume of the particle population is found.

[0052] In certain embodiments of the first and ninth aspects, the microparticles or nanoparticles have an average effective particle size (D v 50) and D of about 1.8 μm to about 7 μm v 90 or an average effective particle size (D v 50) and D of about 2.5 μm to about 6.5 μm v 90, and for any embodiment, the average effective particle size is D v In alternative embodiments of the first and ninth aspects, the microparticles or nanoparticles have an average effective particle size (D v 50) and D of about 2.5 μm to about 4 μm v90, and for any embodiment, the average effective particle size is D v In alternative embodiments of the first and ninth aspects, the microparticles or nanoparticles have an average effective particle size (D v 50) and D of about 3.5 μm to about 5.5 μm v 90, and for any embodiment, the average effective particle size is D v In alternative embodiments of the first and ninth aspects, the microparticles or nanoparticles have an average effective particle size (D v 50) and D of about 5.0 μm to about 6.5 μm v 90, and for any embodiment, the average effective particle size is D v Less than 90.

[0053] As can be seen from Example 3, D of about 1 μm to about 10 μm v It has been surprisingly found that administration of rilpivirine in the form of microparticles or nanoparticles having a particle size of 90 reduces, i.e., flattens, the dissolution profile of rilpivirine. Thus, particle sizes in this range modulate rilpivirine exposure, flattening the pharmacokinetic curve, i.e., reducing the Cmax of the pharmacokinetic curve, while maintaining sustained or prolonged release of rilpivirine into plasma.

[0054] As used herein, the average effective particle size, i.e., the volume-based median particle size (D v 50) and D v 90 is determined by conventional laser diffraction techniques, for example in accordance with ISO 13320:2009.

[0055] Laser diffraction relies on the principle that particles scatter light at angles that vary depending on the particle's size, producing a scattered light pattern defined by intensity and angle that can be correlated to particle size distribution. Many laser diffraction instruments are commercially available for rapid and reliable measurement of particle size distribution. For example, particle size distribution can be measured using a conventional Malvern Mastersizer TM3000 particle size analyzer manufactured by Malvern Instruments. The Malvern Mastersizer TM3000 particle size analyzer operates by projecting a helium-neon gas laser beam through a transparent cell containing particles of interest suspended in an aqueous solution. Light striking the particles is scattered at angles inversely proportional to particle size, and a photodetector array measures the light intensity at several predetermined angles. The measured intensities at different angles are processed by a computer using standard theoretical principles to determine the particle size distribution. Laser diffraction values ​​can be obtained using a wet dispersion of particles in distilled water.

[0056] Volume-based median particle size (D v 50) and D v Other methods commonly used in the art for measuring 90 include disk centrifugation, scanning electron microscopy (SEM), sedimentation field flow fractionation, and photon correlation spectroscopy.

[0057] In one embodiment of the first and ninth aspects of the invention, the microparticles or nanoparticles have one or more surface modifiers adsorbed to their surface.

[0058] Surface modifiers may be selected from known organic and inorganic pharmaceutical excipients, including various polymers, low molecular weight oligomers, natural products, and surfactants. Particular surface modifiers that may be used in the present invention include nonionic surfactants and anionic surfactants. Representative examples of surface modifiers include gelatin, casein, lecithin, salts of negatively charged phospholipids or their acid forms (phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphoric acid, and salts thereof, such as alkali metal salts, e.g., their sodium salts, e.g., egg phosphatidylglycerol sodium, such as products available under the trade name Lipoid™ EPG), gum acacia, stearic acid, benzalkonium chloride, polyoxyethylene alkyl ethers, e.g., macrogol ethers, such as Cetomacrogol 1000, polyoxyethylene castor oil derivatives; polyoxyethylene stearate, colloidal silicon dioxide, sodium dodecyl sulfate, sodium carboxymethylcellulose, bile salts, such as sodium taurocholate, sodium desoxytaurocholate, sodium desoxycholate; methylcellulose, hydroxyethylcellulose, hydroxypropyl ... hydroxypropyl methylcellulose, magnesium aluminosilicate, polyvinyl alcohol (PVA), poloxamers such as Pluronic™ F68, F108, and F127, which are block copolymers of ethylene oxide and propylene oxide; tyloxapol; vitamin E-TGPS (α-tocopheryl polyethylene glycol succinate, particularly α-tocopheryl polyethylene glycol 1000 succinate); poloxamines such as Tetronic™ 908 (T908), a tetrafunctional block copolymer derived from the sequential addition of ethylene oxide and propylene oxide to ethylenediamine; dextran; lecithin; dioctyl esters of sodium sulfosuccinate, such as the product sold under the trade name AerosolOT™ (AOT); sodium lauryl sulfate (Duponol™ P); alkylaryl polyether sulfonate available under the trade name Triton™ X-200;Examples of suitable surface modifiers include polyoxyethylene sorbitan fatty acid esters (Tweens™ 20, 40, 60, and 80); sorbitan esters of fatty acids (Span™ 20, 40, 60, and 80 or Arlacel™ 20, 40, 60, and 80); polyethylene glycols (such as those sold under the trade names Carbowax™ 3550 and 934); mixtures of sucrose stearate and sucrose distearate, such as those available under the trade names Crodesta™ F110 or Crodesta™ SL-40; hexyldecyltrimethylammonium chloride (CTAC); and polyvinylpyrrolidone (PVP). If desired, two or more surface modifiers may be used in combination.

[0059] In one embodiment of the first and ninth aspects of the invention, the surface modifier is selected from poloxamer, α-tocopheryl polyethylene glycol succinate, polyoxyethylene sorbitan fatty acid ester, and a salt or acid form of a negatively charged phospholipid. In preferred embodiments of the first and ninth aspects of the invention, the surface modifier is selected from Pluronic™ F108, Vitamin ETGPS, Tween™ 80, and Lipoid™ EPG.

[0060] In one embodiment of the first and ninth aspects of the invention, the surface modifier is a poloxamer, in particular Pluronic™ F108. Pluronic™ F108 corresponds to poloxamer 338 and has the formula HO-[CH2CHO] where the average values ​​of x, y, and z are 128, 54, and 128, respectively. x -[CH(CH3)CH2O] y -[CH2CH2O] z-H. Other trade names for poloxamer 338 are Hodag Nonionic™ 1108-F and Synperonic™ PE / F 108. In one embodiment of the first and ninth aspects of the invention, the surface modifier comprises a combination of a polyoxyethylene sorbitan fatty acid ester and a phosphatidylglycerol salt (particularly egg sodium phosphatidylglycerol).

[0061] In one embodiment of the first and ninth aspects of the present invention, the relative amounts (w / w) of rilpivirine or a pharmaceutically acceptable salt thereof and surface modifier are about 1:2 to about 20:1, particularly about 1:1 to about 10:1, for example about 4:1 to about 6:1, preferably about 6:1.

[0062] In one embodiment of the first and ninth aspects of the present invention, the microparticles or nanoparticles of the present invention comprise rilpivirine or a pharmaceutically acceptable salt thereof, as defined herein, and one or more surface modifiers, as defined herein, wherein the amount of rilpivirine or a pharmaceutically acceptable salt thereof is at least about 50% by weight of the microparticles or nanoparticles, at least about 80% by weight of the microparticles or nanoparticles, at least about 85% by weight of the microparticles or nanoparticles, at least about 90% by weight of the microparticles or nanoparticles, at least about 95% by weight of the microparticles or nanoparticles, or at least about 99% by weight of the microparticles or nanoparticles, particularly in the range of 80% to 90% by weight of the microparticles or nanoparticles, or in the range of 85% to 90% by weight of the microparticles or nanoparticles.

[0063] In one embodiment of the first and ninth aspects of the present invention, the suspension comprises a pharmaceutically acceptable aqueous carrier in which microparticles or nanoparticles of rilpivirine or a pharmaceutically acceptable salt thereof are suspended. The pharmaceutically acceptable aqueous carrier comprises sterile water (e.g., water for injection), optionally mixed with other pharmaceutically acceptable ingredients. The latter includes any component for use in an injectable formulation. These components may be selected from one or more of a suspending agent, a buffering agent, a pH adjusting agent, a preservative, an isotonicity agent, a surface modifier, a chelating agent, and the like. In one embodiment of the first and ninth aspects of the present invention, the component is selected from one or more of a suspending agent, a buffering agent, a pH adjusting agent, and optionally a preservative and an isotonicity agent. Certain materials may function as two or more of these agents simultaneously, for example, acting as both a preservative and a buffering agent, or as both a buffering agent and an isotonicity agent. In one embodiment of the first and ninth aspects of the invention, the component is selected from one or more of a buffering agent, a pH adjusting agent, an isotonicity agent, a chelating agent, and a surface modifier. In one embodiment of the first and ninth aspects of the invention, the component is selected from one or more of a buffering agent, a pH adjusting agent, an isotonicity agent, and a chelating agent.

[0064] In one embodiment of the first and ninth aspects of the present invention, the suspension further comprises a buffering agent and / or a pH adjusting agent. Suitable buffering agents are salts of weak acids and should be used in an amount sufficient to neutralize the dispersion to a very slightly basic (up to a pH value of about 8.5), preferably in the pH range of about 7 to about 7.5. Particular buffering agents are salts of weak acids. Buffers and pH adjusters that can be added can be selected from tartaric acid, maleic acid, glycine, sodium lactate / lactic acid, ascorbic acid, sodium citrate / citric acid, sodium acetate / acetic acid, sodium bicarbonate / carbonic acid, sodium succinate / succinic acid, sodium benzoate / benzoic acid, sodium phosphate, tris(hydroxymethyl)aminomethane, sodium bicarbonate / sodium carbonate, ammonium hydroxide, benzenesulfonic acid, sodium benzoate / acid, diethanolamine, glucono-delta-lactone, hydrochloric acid, hydrogen bromide, lysine, methanesulfonic acid, monoethanolamine, sodium hydroxide, tromethamine, gluconic acid, glyceric acid, glutaric acid, glutamic acid, ethylenediaminetetraacetic acid (EDTA), triethanolamine, and mixtures thereof. In one embodiment of the first and ninth aspects of the present invention, the buffer is a sodium phosphate buffer, such as sodium dihydrogen phosphate monohydrate. In one embodiment, the pH adjuster is sodium hydroxide.

[0065] In one embodiment of the first and ninth aspects of the present invention, the suspension further comprises a preservative. The preservative is an antibacterial agent and antioxidant that can be selected from the group consisting of benzoic acid, benzyl alcohol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), chlorobutol, gallate, hydroxybenzoate, EDTA, phenol, chlorocresol, metacresol, benzethonium chloride, myristyl-γ-picolinium chloride, phenylacetate nitrate, and thimerosal. Radical scavengers include BHA, BHT, vitamin E, and ascorbyl palmitate, and mixtures thereof. Oxygen scavengers include sodium ascorbate, sodium sulfite, L-cysteine, acetylcysteine, methionine, thioglycerol, acetone sodium bisulfite, isoascorbic acid, and hydroxypropyl cyclodextrin. Chelating agents include sodium citrate, sodium EDTA, citric acid, and malic acid. In one embodiment of the first and ninth aspects of the invention, the chelating agent is citric acid, for example citric acid monohydrate.

[0066] In one embodiment of the first and ninth aspects of the present invention, the suspension further comprises an isotonicity agent. Isotonicity agents or tonicity adjusters may be present to ensure the isotonicity of the pharmaceutical composition of the present invention, and include sugars such as glucose, dextrose, sucrose, fructose, trehalose, and lactose; polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, and mannitol. Alternatively, sodium chloride, sodium sulfate, or other suitable inorganic salts may be used to make the solution isotonic. Tonicity adjusters can be used alone or in combination. The suspension conveniently contains 0-10% (w / v), particularly 0-6% (w / v), of the isotonicity agent. Because electrolytes can affect colloidal stability, non-ionic tonicity adjusters, such as glucose and mannitol, are relevant.

[0067] In one embodiment of the first aspect of the present invention, each dose contains up to about 600 mL of the suspension described herein, i.e., the volume of the suspension containing rilpivirine or a pharmaceutically acceptable salt thereof in microparticle or nanoparticle form can have a volume of up to 600 mL. In one embodiment of the first aspect of the present invention, each dose contains about 5 mL to about 600 mL of suspension. In another embodiment of the first aspect of the present invention, each dose contains about 5 mL to about 300 mL of suspension. In another embodiment of the first aspect of the present invention, each dose contains about 5 mL to about 150 mL of suspension. In another embodiment of the first aspect of the present invention, each dose contains about 5 mL to about 25 mL of suspension. In another embodiment of the first aspect of the present invention, each dose contains about 6 mL to about 20 mL of suspension. In another embodiment of the first aspect of the present invention, each dose contains about 6 mL to about 18 mL of suspension. In another embodiment of the first aspect of the present invention, each dose contains about 6 mL to about 15 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 6 mL to about 12 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 9 mL to about 18 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 9 mL to about 15 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 9 mL to about 12 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 6 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 9 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 12 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 15 mL of suspension. In another embodiment of the first aspect of the invention, each dose comprises about 18 mL of suspension. In one embodiment of the first aspect of the invention, the rilpivirine suspension contains 300 mg rilpivirine / mL.

[0068] In one embodiment, the rilpivirine or pharmaceutically acceptable salt thereof (in the form of microparticles or nanoparticles in suspension) of the first aspect of the invention is provided in a pharmaceutical composition separate from the hyaluronidase. As discussed further herein (e.g., in the section entitled "Uses of Rilpivirine or Pharmaceutically Acceptable Salts Thereof and Hyaluronidase in the Invention"), the separate pharmaceutical compositions may be administered sequentially with the pharmaceutical composition comprising the hyaluronidase of the first aspect of the invention, or the separate pharmaceutical compositions may be mixed with the pharmaceutical composition comprising the hyaluronidase of the invention and the resulting combined pharmaceutical composition may then be administered.

[0069] In another embodiment, the rilpivirine or pharmaceutically acceptable salt thereof of the first aspect of the invention (in the form of microparticles or nanoparticles in suspension) is provided in the same pharmaceutical composition as the hyaluronidase, i.e., the rilpivirine or pharmaceutically acceptable salt thereof is formulated in a combined pharmaceutical composition with the hyaluronidase.

[0070] In one embodiment of the first aspect of the present invention, for the treatment of HIV infection, the administered dose can be calculated based on about 300 mg to about 1200 mg per month, or about 450 mg to about 1200 mg per month, or about 450 mg to about 900 mg per month, or about 600 mg to about 900 mg per month, or about 450 mg to about 750 mg per month, or 450 mg per month, or 600 mg per month, or 750 mg per month, or 900 mg per month. Doses for other dosing regimens can be easily calculated by multiplying the monthly dose by the number of months between each administration. For example, for a 450 mg per month dose and a 6-month time interval between each administration, the dose administered in each administration is 2700 mg. The "mg" indicated corresponds to mg of rilpivirine (i.e., rilpivirine in its free base form). Thus, by way of example, 1 mg of rilpivirine (ie, rilpivirine in its free base form) is equivalent to 1.1 mg of rilpivirine hydrochloride.

[0071] In one embodiment of the first aspect of the present invention, for the treatment of HIV infection, the administered dose can be calculated based on about 300 mg to about 1200 mg per 4 weeks (28 days), or about 450 mg to about 1200 mg per 4 weeks (28 days), or about 450 mg to about 900 mg per 4 weeks (28 days), or about 600 mg to about 900 mg per 4 weeks (28 days), or about 450 mg to about 750 mg per 4 weeks (28 days), or 450 mg per 4 weeks (28 days), or 600 mg per 4 weeks (28 days), or 750 mg per 4 weeks (28 days), or 900 mg per 4 weeks (28 days). Doses for other dosing regimens can be easily calculated by multiplying the weekly or daily dose by the number of weeks between each administration. For example, in the case of a dose of 450 mg / 4 weeks (28 days) and a time interval between each administration of 24 weeks, the dose administered in each administration is 2700 mg. Or, for example, in the case of a dose of 750 mg / 4 weeks (28 days) and a time interval between each administration of 24 weeks, the dose administered in each administration is 4500 mg. The "mg" indicated corresponds to mg of rilpivirine (i.e., rilpivirine in its free base form). Thus, for example, 1 mg of rilpivirine (i.e., rilpivirine in free base form) is equivalent to 1.1 mg of rilpivirine hydrochloride.

[0072] In one embodiment of the first aspect of the present invention, for the treatment of HIV infection, each dose of rilpivirine or a pharmaceutically acceptable salt thereof is about 900 mg to about 28,800 mg (e.g., about 900 mg to about 14,400 mg, or about 900 mg to about 7,200 mg, or about 900 mg to about 3,600 mg), preferably about 1,200 mg to about 14,400 mg, preferably about 1,350 mg to about 13,200 mg. , preferably about 1500 mg to about 12000 mg (e.g., about 3000 mg to about 12000 mg), preferably about 1800 mg to about 10800 mg (e.g., about 2700 mg to about 10800 mg, or about 1800 mg to about 3600 mg), and most preferably about 1800 mg to about 7200 mg or about 2700 mg to about 4500 mg of rilpivirine or a pharmaceutically acceptable salt thereof.

[0073] Therefore, the amount of rilpivirine or a pharmaceutically acceptable salt thereof in the pharmaceutical composition, i.e., the separate or combined pharmaceutical composition defined herein in connection with the first aspect of the present invention, can be about 900 mg to about 28,800 mg (e.g., about 900 mg to about 14,400 mg, or about 900 mg to about 7,200 mg, or about 900 mg to about 3,600 mg), preferably about 1,200 mg to about 14,400 mg, preferably about 1,350 mg to about 13,200 mg, preferably about 1,500 mg to about 12,000 mg (e.g., about 3,000 mg to about 12,000 mg), preferably about 1,800 mg to about 10,800 mg (e.g., about 2,700 mg to about 10,800 mg, or about 1,800 mg to about 3,600 mg), and most preferably about 1,800 mg to about 7,200 mg or about 2,700 mg to about 4,500 mg. The "mg" shown corresponds to mg of rilpivirine (i.e., rilpivirine in its free base form). Thus, by way of example, 1 mg of rilpivirine (i.e., rilpivirine in its free base form) is equivalent to 1.1 mg of rilpivirine hydrochloride.

[0074] In the case of prevention of HIV infection, each administration of rilpivirine or a pharmaceutically acceptable salt thereof may comprise the same dose as in the therapeutic application as described above.

[0075] In one embodiment of the first aspect of the present invention, the rilpivirine or pharmaceutically acceptable salt thereof in the pharmaceutical composition, i.e., separate or combined pharmaceutical compositions as defined herein, is used in an amount such that the plasma concentration of rilpivirine in the subject is maintained at a level greater than about 12 ng / ml, preferably in the range of about 12 ng / ml to about 100 ng / ml, more preferably about 12 ng / ml to about 50 ng / ml, for at least three months after administration, or at least six months after administration, or at least nine months after administration, or at least one year after administration, or at least two years after each administration. In a preferred embodiment of the first aspect of the present invention, the rilpivirine or pharmaceutically acceptable salt thereof in the pharmaceutical composition is used in an amount such that the plasma concentration of rilpivirine in the subject is maintained at a level of 12 ng / ml to 100 ng / ml for at least six months.

[0076] In certain embodiments of the first aspect of the invention, rilpivirine or a pharmaceutically acceptable salt thereof is formulated and administered as microparticles or nanoparticles in a suspension, the formulation comprising the following components: Rilpivirine or a pharmaceutically acceptable salt thereof, in particular rilpivirine; a surface modifier as defined herein, in particular poloxamer 338, isotonic agents, especially glucose monohydrate; buffering agents, especially sodium dihydrogen phosphate; chelating agents, especially citric acid monohydrate, pH adjusters, especially sodium hydroxide, and Water, especially water for injection.

[0077] In another particular embodiment of the first aspect of the invention, rilpivirine or a pharmaceutically acceptable salt thereof is formulated and administered as microparticles or nanoparticles in a suspension, the formulation comprising the following components: Rilpivirine or a pharmaceutically acceptable salt thereof, in particular rilpivirine; Poloxamer 338, glucose monohydrate, sodium dihydrogen phosphate, citric acid monohydrate, sodium hydroxide, and Water, especially water for injection.

[0078] In one embodiment of the first and ninth aspects of the invention, the aqueous suspension may comprise, by weight based on the total volume of the suspension: (a) 3% to 50% (w / v), or 10% to 40% (w / v), or 10% to 30% (w / v) of rilpivirine or a pharmaceutically acceptable salt thereof, in particular rilpivirine; (b) 0.5% to 10% (w / v), or 0.5% to 5% (w / v), or 0.5% to 2% (w / v) of a surface modifier, particularly poloxamer 338; (c) 0% to 10% (w / v), or 0% to 5% (w / v), or 0% to 2% (w / v), or 0% to 1% (w / v) of one or more buffering agents, in particular sodium dihydrogen phosphate; (d) 0% to 10% (w / v), or 0% to 6% (w / v), or 0% to 5% (w / v), or 0% to 3% (w / v), or 0% to 2% (w / v) of an isotonic agent, in particular glucose monohydrate; (e) 0% to 2% (w / v), or 0% to 1% (w / v), or 0% to 0.5% (w / v), or 0% to 0.1% (w / v) of a pH adjuster, particularly sodium hydroxide; (f) 0% to 2% (w / v), or 0% to 1% (w / v), or 0% to 0.5% (w / v), or 0% to 0.1% (w / v) of a chelating agent, in particular citric acid monohydrate; (g) 0% to 2% (w / v) of a preservative, and (h) Water for injection up to 100%.

[0079] In one embodiment of the first and ninth aspects of the invention, the aqueous suspension may comprise, by weight based on the total volume of the suspension: (a) 3% to 50% (w / v), or 10% to 40% (w / v), or 10% to 30% (w / v) of rilpivirine or a pharmaceutically acceptable salt thereof, in particular rilpivirine; (b) 0.5% to 10% (w / v), or 0.5% to 5% (w / v), or 0.5% to 2% (w / v) of a surface modifier, particularly poloxamer 338; (c) 0% to 10% (w / v), or 0% to 5% (w / v), or 0% to 2% (w / v), or 0% to 1% (w / v) of one or more buffering agents, in particular sodium dihydrogen phosphate; (d) 0% to 10% (w / v), or 0% to 6% (w / v), or 0% to 5% (w / v), or 0% to 3% (w / v), or 0% to 2% (w / v) of an isotonic agent, in particular glucose monohydrate; (e) 0% to 2% (w / v), or 0% to 1% (w / v), or 0% to 0.5% (w / v), or 0% to 0.1% (w / v) of a pH adjuster, particularly sodium hydroxide; (f) 0% to 2% (w / v), or 0% to 1% (w / v), or 0% to 0.5% (w / v), or 0% to 0.1% (w / v) of a chelating agent, in particular citric acid monohydrate, and (g) Water for injection up to 100%.

[0080] In certain embodiments of the first aspect of the invention, rilpivirine or a pharmaceutically acceptable salt thereof is formulated (and administered) as a suspension of microparticles or nanoparticles, the suspension comprising the following components in the following amounts: (a) Rilpivirine (300 mg), (b) poloxamer 338 (50 mg), and (c) Water for injection (up to 1 mL).

[0081] Alternatively, the ingredients can be used in different amounts, but with the same weight ratio between the ingredients and the total volume (made up by water for injection) scaled by the same value.

[0082] In certain embodiments of the first aspect of the invention, rilpivirine or a pharmaceutically acceptable salt thereof is formulated (and administered) as a suspension of microparticles or nanoparticles, the suspension comprising the following components in the following amounts: a. Rilpivirine (300 mg), b. Poloxamer 338 (50 mg), c. glucose monohydrate (19.25 mg), d. Sodium dihydrogen phosphate (2.00 mg), e. Citric acid monohydrate (1.00 mg), f. Sodium hydroxide (0.866 mg), and g. Water for injection (up to 1 mL).

[0083] Alternatively, the ingredients can be used in different amounts, but with the same weight ratio between the ingredients and the total volume (made up by water for injection) scaled by the same value.

[0084] In one embodiment of the first aspect of the present invention, the suspension of rilpivirine or a pharmaceutically acceptable salt thereof described herein is administered by a manual injection process.

[0085] In one embodiment of the ninth aspect of the present invention, the amount of rilpivirine or a pharmaceutically acceptable salt thereof in the suspension or pharmaceutical composition of the present invention is about 900 mg to about 28,800 mg (e.g., about 900 mg to about 14,400 mg, or about 900 mg to about 7,200 mg, or about 900 mg to about 3,600 mg), preferably about 1,200 mg to about 14,400 mg, preferably about 1,350 mg to about 13,200 mg, preferably about 1,500 mg to about 12,000 mg (e.g., about 3,000 mg to about 12,000 mg), preferably about 1,800 mg to about 10,800 mg (e.g., about 2,700 mg to about 10,800 mg, or about 1,800 mg to about 3,600 mg), and most preferably about 1,800 mg to about 7,200 mg, or about 2,700 mg to about 4,500 mg. The "mg" shown corresponds to mg of rilpivirine (i.e., rilpivirine in its free base form). Thus, by way of example, 1 mg of rilpivirine (i.e., rilpivirine in its free base form) is equivalent to 1.1 mg of rilpivirine hydrochloride.

[0086] In one embodiment, the suspension of the ninth aspect of the invention is formulated for administration by subcutaneous or intramuscular injection. In a preferred embodiment of the ninth aspect of the invention, the suspension of the invention is formulated for administration by subcutaneous injection.

[0087] In certain embodiments, the rilpivirine or pharmaceutically acceptable salt thereof of the ninth aspect of the invention is formulated into a formulation comprising the following ingredients: Rilpivirine or a pharmaceutically acceptable salt thereof, in particular rilpivirine in a suspension as defined herein; a surface modifier as defined herein, in particular poloxamer 338, isotonic agents, especially glucose monohydrate; buffering agents, especially sodium dihydrogen phosphate; chelating agents, especially citric acid monohydrate, pH adjusters, especially sodium hydroxide, and Water, especially water for injection.

[0088] In certain embodiments, the rilpivirine or pharmaceutically acceptable salt thereof of the ninth aspect of the invention is formulated into a formulation comprising the following ingredients: Rilpivirine or a pharmaceutically acceptable salt thereof, in particular rilpivirine in a suspension as defined herein; Poloxamer 338, glucose monohydrate, sodium dihydrogen phosphate, citric acid monohydrate, sodium hydroxide, and Water, especially water for injection.

[0089] In certain embodiments of the ninth aspect of the invention, rilpivirine or a pharmaceutically acceptable salt thereof is formulated as a microparticulate or nanoparticulate suspension, the suspension comprising the following components in the following amounts: (a) Rilpivirine (300 mg), (b) poloxamer 338 (50 mg), and (c) Water for injection (up to 1 mL).

[0090] Alternatively, the ingredients can be used in different amounts, but with the same weight ratio between the ingredients and the total volume (made up by water for injection) scaled by the same value.

[0091] In certain embodiments, the rilpivirine or pharmaceutically acceptable salt thereof of the ninth aspect of the invention is formulated into a formulation comprising the following ingredients in the following amounts: (a) rilpivirine (300 mg) in the form of microparticles or nanoparticles in a suspension as defined herein; (b) Poloxamer 338 (50 mg), (c) glucose monohydrate (19.25 mg); (d) sodium dihydrogen phosphate (2.00 mg), (e) citric acid monohydrate (1.00 mg), (f) sodium hydroxide (0.866 mg), and (g) Water for injection (up to 1 mL).

[0092] Alternatively, the ingredients can be used in different amounts, but with the same weight ratio between the ingredients and the total volume (made up by water for injection) scaled by the same value.

[0093] For the avoidance of doubt, each of the embodiments described in this section in relation to the first aspect of the invention applies equally, i.e., is also disclosed in combination with aspects 2 to 8 of the invention. Furthermore, each of the embodiments described in this section in relation to the ninth aspect of the invention applies equally, i.e., is also disclosed in combination with aspects 10 to 13 of the invention.

[0094] hyaluronidase Hyaluronidase is an enzyme that degrades hyaluronic acid (HA) and reduces the viscosity of hyaluronan in the extracellular matrix. This property allows it to be used to increase the dispersion and absorption of injected active pharmaceutical ingredients. The enzymatic activity of hyaluronidase, including rHuPH20, can be defined as units per mL (U / mL) or total enzyme activity (U) in a particular formulation.

[0095] It is generally known that delivery of hyaluronidase (EC 3.2.1.35 / 36) to tissues improves drug penetration, and therefore administration of hyaluronidase represents a method to increase drug distribution and improve absorption.

[0096] Administration of high doses of rilpivirine or a pharmaceutically acceptable salt thereof can result in the formation of a bump at the injection site, and administration of hyaluronidase together with rilpivirine or a pharmaceutically acceptable salt thereof according to the first aspect of the present invention can reduce such bump formation.

[0097] As used herein, the term "hyaluronidase" refers to any enzyme that degrades hyaluronic acid and reduces the viscosity of hyaluronan in the extracellular matrix.

[0098] In preferred embodiments of the first aspect of the invention, the hyaluronidase is a recombinant hyaluronidase. In particularly preferred embodiments of the first aspect of the invention, the hyaluronidase is a recombinant human hyaluronidase, such as rHuPH20. In one embodiment of the first aspect of the invention, rHuPH20 is defined by the amino acid sequence available under CAS Registry Number 757971-58-7. Further information regarding rHuPH20 is provided in WO 2004 / 078140. In one embodiment of the first aspect of the invention, the amino acid sequence of rHuPH20 comprises SEQ ID NO: 1. In some embodiments of the first aspect of the invention, the hyaluronidase is a variant of rHuPH20 having the amino acid sequence of SEQ ID NO: 2, i.e., rHuPH20 comprising residues 36-482 of wild-type human hyaluronidase. In some embodiments of the first aspect of the invention, the hyaluronidase is a variant of rHuPH20 having the amino acid sequence of SEQ ID NO: 3. In some embodiments of the first aspect of the invention, the hyaluronidase is a variant of rHuPH20 having an amino acid sequence comprising SEQ ID NO: 4. In some embodiments of the first aspect of the invention, the hyaluronidase is a variant of rHuPH20 having an amino acid sequence comprising SEQ ID NO: 5.

[0099] [Table 1]

[0100] In one embodiment of the first aspect of the present invention, the hyaluronidase of the present invention is formulated in a separate pharmaceutical composition. As discussed further herein (e.g., in the sections entitled "Uses of Rilpivirine or a Pharmaceutically Acceptable Salt Thereof and Hyaluronidase in the First to Eighth Aspects of the Present Invention, and Uses of Rilpivirine or a Pharmaceutically Acceptable Salt Thereof in the Ninth to Thirteenth Aspects of the Present Invention"), the separate pharmaceutical composition may be administered sequentially with the pharmaceutical composition comprising rilpivirine or a pharmaceutically acceptable salt thereof, or the separate pharmaceutical composition may be optionally mixed with the pharmaceutical composition comprising rilpivirine or a pharmaceutically acceptable salt thereof, and the resulting combined pharmaceutical composition may then be administered.

[0101] In another embodiment, the hyaluronidase of the first aspect of the invention is formulated in the same pharmaceutical composition as rilpivirine or a pharmaceutically acceptable salt thereof, i.e., the hyaluronidase is formulated as a combined pharmaceutical composition (with rilpivirine or a pharmaceutically acceptable salt thereof).

[0102] In one embodiment of the first aspect of the present invention, the hyaluronidase is in the form of a solution, and preferably, the concentration of the hyaluronidase in the solution is about 50 to about 20,000 U / mL, preferably about 50 to about 10,000 U / mL, about 50 to about 5000 U / mL, or about 500 to about 2000 U / mL. In one embodiment of the first aspect of the present invention, the hyaluronidase is in the form of a solution, and preferably, the concentration of the hyaluronidase in the solution is about 500 U / mL. In one embodiment of the first aspect of the present invention, the hyaluronidase is in the form of a solution, and preferably, the concentration of the hyaluronidase in the solution is about 750 U / mL. In one embodiment of the first aspect of the present invention, the hyaluronidase is in the form of a solution, and preferably, the concentration of the hyaluronidase in the solution is about 1000 U / mL. In one embodiment of the first aspect of the present invention, the hyaluronidase is in the form of a solution, preferably having a concentration of about 1250 U / mL. In one embodiment of the first aspect of the present invention, the hyaluronidase is in the form of a solution, preferably having a concentration of about 1500 U / mL. In one embodiment of the first aspect of the present invention, the hyaluronidase is in the form of a solution, preferably having a concentration of about 1750 U / mL. In one embodiment of the first aspect of the present invention, the hyaluronidase is in the form of a solution, preferably having a concentration of about 2000 U / mL.

[0103] In some embodiments of the first aspect of the invention, the hyaluronidase-containing composition comprises about 1,000 U, 2,000 U, 3,000 U, 4,000 U, about 5,000 U, about 6,000 U, about 7,000 U, about 8,000 U, about 9,000 U, about 10,000 U, about 11,000 U, about 12,000 U, about 13,000 U, about 14,000 U, about 15,000 U, about 16,000 U, about 17,000 U, about 18,000 U, about 19,000 U, about The hyaluronidase may be present in a dose of 20,000 U, about 21,000 U, about 22,000 U, about 23,000 U, about 24,000 U, about 25,000 U, about 26,000 U, about 27,000 U, about 30,000 U, about 31,000 U, about 32,000 U, about 33,000 U, about 34,000 U, about 35,000 U, about 36,000 U, about 37,000 U, about 38,000 U, about 39,000 U, about 40,000 U, or any value therebetween. In some embodiments of the first aspect of the invention, when the hyaluronidase is administered sequentially with a pharmaceutical composition comprising rilpivirine or a pharmaceutically acceptable salt thereof, the hyaluronidase-containing composition comprises hyaluronidase at a dose of about 1,000 U, 2,000 U, 3,000 U, 4,000 U, about 5,000 U, about 6,000 U, about 7,000 U, about 8,000 U, about 9,000 U, about 10,000 U, or any value therebetween. In a preferred embodiment of the first aspect of the invention, the hyaluronidase-containing composition comprises hyaluronidase at a dose of about 2,000 U.In some embodiments of the first aspect of the present invention, when hyaluronidase is mixed with a pharmaceutical composition comprising rilpivirine or a pharmaceutically acceptable salt thereof as needed prior to administration of the resulting mixed pharmaceutical composition, the mixed composition contains about 11,000 U, about 12,000 U, about 13,000 U, about 14,000 U, about 15,000 U, about 16,000 U, about 17,000 U, about 18,000 U, about 19,000 U, about 20,000 U, or In a preferred embodiment of the first aspect of the present invention, the mixed composition comprises hyaluronidase at a dose of about 18,000 U or 30,000 U.

[0104] In certain embodiments of the first aspect of the present invention, the hyaluronidase is formulated as a solution in a separate pharmaceutical composition, i.e., a solution that does not include rilpivirine or a pharmaceutically acceptable salt thereof, and the separate pharmaceutical composition comprises the following components: Approximately 50 U / mL to approximately 10,000 U / mL of rHuPH20, about 5 mM to about 50 mM histidine, about 50 mM to about 400 mM sorbitol; about 0.1 mg / mL to about 2.5 mg / mL of methionine; Approximately 0.01% (w / v) to approximately 0.1% (w / v) polysorbate 20.

[0105] For the avoidance of doubt, each of the embodiments described in this section with respect to the first aspect of the present invention applies equally, i.e., is also disclosed in combination with the second to eighth aspects of the present invention.

[0106] Use of rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase in the first to eighth aspects of the present invention, and use of rilpivirine or a pharmaceutically acceptable salt thereof in the ninth to thirteenth aspects of the present invention. In a first aspect of the present invention, there is provided a method for the treatment or prevention of HIV infection in a subject in need thereof, the method comprising administering to the subject by intramuscular or subcutaneous injection a therapeutically effective amount of rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension, wherein the rilpivirine or pharmaceutically acceptable salt thereof is administered in combination with hyaluronidase administered by intramuscular or subcutaneous injection, and wherein the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at time intervals of from about 3 months to about 2 years.

[0107] Thus, the methods for treatment or prevention according to the first aspect of the present invention described herein comprise multiple administrations of rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein the time interval between each administration of rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase and a subsequent administration of rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase is from about 3 months to about 2 years, i.e., rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase according to the first aspect of the present invention is administered to a subject as described herein, followed by a time interval of 3 months to 2 years, whereby rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase according to the present invention is again administered to the subject as defined herein.

[0108] In an eleventh aspect of the present invention, there is provided rilpivirine or a pharmaceutically acceptable salt thereof according to the ninth aspect of the present invention for use in the treatment or prevention of HIV infection in a subject, namely rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in suspension, wherein the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v 90 or a pharmaceutically acceptable salt thereof is provided.

[0109] As used herein in connection with the therapeutic or prophylactic methods and uses described herein, the terms "is administered" and "are administered" can encompass the terms "is to be administered" and "are to be administered," respectively.

[0110] In a preferred embodiment of the first or eleventh aspect of the invention, the subject is a human.

[0111] In the first aspect of the present invention, rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase may be administered simultaneously or sequentially. In one embodiment of the first aspect of the present invention, rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered sequentially, i.e., one after the other, preferably within 24 hours of each other, preferably within 1 hour of each other, preferably within 30 minutes of each other, preferably within 10 minutes of each other, and more preferably within 5 minutes of each other. Preferably, hyaluronidase is administered before administration of rilpivirine or a pharmaceutically acceptable salt thereof. In another embodiment of the first aspect of the present invention, rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered simultaneously.

[0112] When the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase of the first aspect of the invention are administered sequentially, they are formulated in separate pharmaceutical compositions, which are further described herein in the sections entitled "Rilpivirine" and "Hyaluronidase."

[0113] When the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase of the first aspect of the present invention are administered sequentially, they are both administered by the same method, i.e., subcutaneous injection or intramuscular injection. Furthermore, they are both administered at the same site. By the same site, it is meant that the injection sites are within 15 cm of each other, within 12 cm of each other, or within 8 cm of each other. Preferably, the injection sites are within 10 cm of each other, more preferably within 5 cm of each other, and even more preferably within 1 cm of each other. This allows the hyaluronidase to exert the effect of increasing the tolerability of the injection of rilpivirine or a pharmaceutically acceptable salt thereof.

[0114] When the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase of the first aspect of the present invention are administered simultaneously, they may both be administered at the same site, i.e., via the same syringe / needle. When the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase of the first aspect of the present invention are administered simultaneously, the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase may be provided in a combined pharmaceutical composition, i.e., a pharmaceutical composition containing both rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase. This combined pharmaceutical composition is further described herein in the sections entitled "Rilpivirine" and "Hyaluronidase." When the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase of the first aspect of the present invention are administered simultaneously, the rilpivirine or pharmaceutically acceptable salt thereof and hyaluronidase may be provided as separate pharmaceutical compositions that are mixed (to provide a combined pharmaceutical formulation, if necessary, prior to administration).

[0115] The pharmaceutical combination composition of the first aspect of the present invention is surprisingly stable upon storage, i.e., the hyaluronidase remains active even after combination with rilpivirine or a pharmaceutically acceptable salt thereof when stored as needed prior to administration, for example, at room temperature for at least 4 hours, or 24 hours or more, particularly at 2-8°C.

[0116] In one embodiment, the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase of the first aspect of the invention are administered sequentially to the same injection site, for example, through the same needle that has not been removed from the injection site, e.g., the skin.

[0117] In the first aspect of the present invention, rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered such that the time interval between administrations (i.e., the administration interval) is about 3 months to about 2 years. That is, rilpivirine or a pharmaceutically acceptable salt thereof is administered together with hyaluronidase (e.g., simultaneously or consecutively), and then, after a time interval of about 3 months to about 1 year, rilpivirine or a pharmaceutically acceptable salt thereof is again administered together with hyaluronidase (e.g., simultaneously or consecutively).

[0118] It has been found that administration of rilpivirine or a pharmaceutically acceptable salt thereof together with the hyaluronidase of the first aspect of the invention as defined herein can maintain sustained, extended or prolonged release of rilpivirine when administered by intramuscular or subcutaneous injection in the form of microparticles or nanoparticles in a suspension. This surprising effect is discussed in detail in Examples 1 and 2.

[0119] In one embodiment, the treatment or prevention according to the eleventh aspect of the invention comprises multiple, i.e., intermittent, administration of rilpivirine or a pharmaceutically acceptable salt thereof, wherein the time interval between administration of rilpivirine or a pharmaceutically acceptable salt thereof and a subsequent administration of rilpivirine or a pharmaceutically acceptable salt thereof (i.e., the administration interval) is from about 3 months to about 2 years, i.e., rilpivirine or a pharmaceutically acceptable salt thereof according to the eleventh aspect of the invention is administered to a subject as described herein, followed by again administering rilpivirine or a pharmaceutically acceptable salt thereof according to the eleventh aspect of the invention to a subject as defined herein after a time interval of from about 3 months to about 2 years.

[0120] In one embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 1.5 years. In one embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 2 years. In a preferred embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 3 months to about 1.5 years. In another preferred embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 3 months to about 1 year. In another preferred embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 3 months to about 6 months. In another preferred embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 6 months to about 1 year. In another preferred embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 3 months. In another preferred embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 6 months. In another preferred embodiment of the first and eleventh aspects of the present invention, the time interval described herein is about 1 year.

[0121] The rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase of the first aspect of the invention are administered by subcutaneous or intramuscular injection. Preferably, the rilpivirine and the hyaluronidase of the first aspect of the invention are administered by subcutaneous injection (either in the same combined pharmaceutical composition or in separate pharmaceutical compositions).

[0122] In one embodiment of the eleventh aspect of the present invention, rilpivirine or a pharmaceutically acceptable salt thereof is administered by subcutaneous injection or intramuscular injection. Preferably, rilpivirine or a pharmaceutically acceptable salt thereof is administered by subcutaneous injection.

[0123] In one embodiment of the eleventh aspect of the present invention, rilpivirine or a pharmaceutically acceptable salt thereof is administered by a manual injection process.

[0124] The rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase of the first aspect of the present invention, and the rilpivirine or a pharmaceutically acceptable salt thereof of the eleventh aspect of the present invention, are used in methods for treating or preventing HIV infection in a subject, i.e., the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase of the first aspect of the present invention defined herein, and the rilpivirine or a pharmaceutically acceptable salt thereof of the eleventh aspect of the present invention defined herein are for use in the treatment or prevention of HIV infection. The rilpivirine or a pharmaceutically acceptable salt thereof is administered in a therapeutically effective amount. "Therapeutically effective amount" means an amount sufficient to provide a therapeutic effect.

[0125] In a specific embodiment, the rilpivirine or pharmaceutically acceptable salt thereof used in the first aspect of the present invention is rilpivirine, and rilpivirine and hyaluronidase are used in a method for treating HIV infection in a subject in need thereof, as described herein, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine is suspended in the form of microparticles or nanoparticles, the rilpivirine and hyaluronidase are administered by subcutaneous injection, preferably the microparticles or nanoparticles have an average effective particle size of about 100 nm to about 300 nm, and preferably a surface modifier, such as poloxamer 338, is adsorbed to the surface of the microparticles or nanoparticles.

[0126] In a specific embodiment, the rilpivirine or pharmaceutically acceptable salt thereof used in the first aspect of the present invention is rilpivirine, and the rilpivirine and hyaluronidase are used in a method for treating HIV infection in a subject in need thereof, as described herein, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which the rilpivirine is suspended in the form of microparticles or nanoparticles, and the rilpivirine and hyaluronidase are administered by subcutaneous injection, and preferably the microparticles or nanoparticles have a D of about 0.2 μm to about 3 μm. v 50 or D as described herein v50, and preferably a surface modifier, such as poloxamer 338, is adsorbed onto the surface of the microparticles or nanoparticles.

[0127] In a specific embodiment, the rilpivirine or pharmaceutically acceptable salt thereof used in the first aspect of the present invention is rilpivirine, and the rilpivirine and hyaluronidase are used in a method for treating HIV infection in a subject in need thereof, as described herein, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which the rilpivirine is suspended in the form of microparticles or nanoparticles, and the rilpivirine and hyaluronidase are administered by subcutaneous injection, and preferably the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v 90 or D as described herein v 90, and preferably a surface modifier, such as poloxamer 338, is adsorbed onto the surface of the microparticles or nanoparticles.

[0128] In a particular embodiment, in the eleventh aspect of the present invention, the rilpivirine or a pharmaceutically acceptable salt thereof used is rilpivirine, and the rilpivirine is used in a method for treating HIV infection in a subject in need thereof as described herein, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which the rilpivirine is suspended in the form of microparticles or nanoparticles, and the rilpivirine is administered by subcutaneous injection, and preferably the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v In combination with 90, D ranges from about 0.2 μm to about 3 μm v 50 or as described herein v 50 and D v 90 combination, preferably a surface modifier, such as poloxamer 338, is adsorbed onto the surface of the microparticles or nanoparticles.

[0129] In a particular embodiment, the rilpivirine or pharmaceutically acceptable salt thereof in the eleventh aspect of the present invention is rilpivirine, and the rilpivirine is used for the treatment of HIV infection in a subject in need thereof as described herein, and the suspension is a suspension in which the rilpivirine has a D v The rilpivirine is administered by subcutaneous injection and preferably comprises a pharmaceutically acceptable aqueous carrier in which the rilpivirine is suspended in the form of microparticles or nanoparticles having a diameter of 90, and a surface modifier, such as poloxamer 338, is adsorbed onto the surface of the microparticles or nanoparticles.

[0130] In one embodiment, rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase of the first aspect of the invention and rilpivirine or a pharmaceutically acceptable salt thereof of the eleventh aspect of the invention are used in a method for treating or preventing HIV type 1 (HIV-1) infection in a subject, i.e., embodiments described herein relate to the use of rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase as defined herein and the use of rilpivirine or a pharmaceutically acceptable salt thereof of the eleventh aspect of the invention as defined herein for treating or preventing HIV type 1 (HIV-1) infection in a subject.

[0131] In one embodiment of the eleventh aspect of the present invention, each dose contains up to about 600 mL of the suspension described herein, i.e., the volume of the suspension containing rilpivirine or a pharmaceutically acceptable salt thereof can have a volume of up to 600 mL. In one embodiment of the eleventh aspect of the present invention, each dose contains about 5 mL to about 600 mL of suspension. In another embodiment of the eleventh aspect of the present invention, each dose contains about 5 mL to about 300 mL of suspension. In another embodiment of the eleventh aspect of the present invention, each dose contains about 5 mL to about 150 mL of suspension. In another embodiment of the eleventh aspect of the present invention, each dose contains about 5 mL to about 25 mL of suspension. In another embodiment of the eleventh aspect of the present invention, each dose contains about 6 mL to about 20 mL of suspension. In another embodiment of the eleventh aspect of the present invention, each dose contains about 6 mL to about 18 mL of suspension. In another embodiment of the eleventh aspect of the present invention, each dose contains about 6 mL to about 15 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 6 mL to about 12 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 9 mL to about 18 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 9 mL to about 15 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 9 mL to about 12 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 6 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 9 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 12 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 15 mL of suspension. In another embodiment of the eleventh aspect of the invention, each dose comprises about 18 mL of suspension. In one embodiment of the eleventh aspect of the invention, the rilpivirine suspension contains 300 mg rilpivirine / mL.

[0132] In one embodiment of the eleventh aspect of the present invention, for the treatment of HIV infection, the administered dose can be calculated based on about 300 mg to about 1200 mg per month, or about 450 mg to about 1200 mg per month, or about 450 mg to about 900 mg per month, or about 450 mg to about 750 mg per month, or about 600 mg to about 900 mg per month, or 450 mg per month, or 600 mg per month, or 750 mg per month, or 900 mg per month. Doses for other dosing regimens can be easily calculated by multiplying the monthly dose by the number of months between each administration. For example, for a 450 mg / month dose and a 6-month interval between each administration, the dose administered in each administration is 2700 mg. Or, for example, for a 750 mg / month dose and a 6-month interval between each administration, the dose administered in each administration is 4500 mg. The "mg" shown corresponds to mg of rilpivirine (i.e., rilpivirine in its free base form). Thus, by way of example, 1 mg of rilpivirine (i.e., rilpivirine in its free base form) is equivalent to 1.1 mg of rilpivirine hydrochloride.

[0133] In one embodiment of the eleventh aspect of the present invention, for the treatment of HIV infection, the administered dose can be calculated based on about 300 mg to about 1200 mg per 4 weeks (28 days), or about 450 mg to about 1200 mg per 4 weeks (28 days), or about 450 mg to about 900 mg per 4 weeks (28 days), or about 450 mg to about 750 mg per 4 weeks (28 days), or about 600 mg to about 900 mg per 4 weeks (28 days), or 450 mg per 4 weeks (28 days), or 600 mg per 4 weeks (28 days), or 750 mg per 4 weeks (28 days), or 900 mg per 4 weeks (28 days). Doses for other dosing regimens can be readily calculated by multiplying the weekly or daily dose by the number of weeks between each administration. For example, in the case of a dose of 450 mg / 4 weeks (28 days) and a time interval between each administration of 24 weeks, the dose administered in each administration is 2700 mg. Or, for example, in the case of a dose of 750 mg / 4 weeks (28 days) and a time interval between each administration of 24 weeks, the dose administered in each administration is 4500 mg. The "mg" indicated corresponds to mg of rilpivirine (i.e., rilpivirine in its free base form). Thus, for example, 1 mg of rilpivirine (i.e., rilpivirine in free base form) is equivalent to 1.1 mg of rilpivirine hydrochloride.

[0134] In one embodiment of the eleventh aspect of the present invention, for the treatment of HIV infection, each administration of rilpivirine or a pharmaceutically acceptable salt thereof is about 900 mg to about 28,800 mg (e.g., about 900 mg to about 14,400 mg, or about 900 mg to about 7,200 mg, or about 900 mg to about 3,600 mg), preferably about 1,200 mg to about 14,400 mg, preferably about 1,350 mg to about 13,200 mg. , preferably about 1500 mg to about 12000 mg (e.g., about 3000 mg to about 12000 mg), preferably about 1800 mg to about 10800 mg (e.g., about 2700 mg to about 10800 mg, or about 1800 mg to about 3600 mg), and most preferably about 1800 mg to about 7200 mg or about 2700 mg to about 4500 mg of rilpivirine or a pharmaceutically acceptable salt thereof.

[0135] In the case of prevention of HIV infection, each administration of rilpivirine or a pharmaceutically acceptable salt thereof according to the eleventh aspect of the invention may comprise the same dose as for therapeutic use as described above.

[0136] In one embodiment of the eleventh aspect of the present invention, rilpivirine or a pharmaceutically acceptable salt thereof is used in an amount such that the plasma concentration of rilpivirine in the subject is maintained at a level of greater than about 12 ng / ml, preferably in the range of about 12 ng / ml to about 100 ng / ml, more preferably about 12 ng / ml to about 50 ng / ml, for at least three months after administration, or at least six months after administration, or at least nine months after administration, or at least one year after administration, or at least two years after each administration. In a preferred embodiment of the eleventh aspect of the present invention, rilpivirine or a pharmaceutically acceptable salt thereof is used in an amount such that the plasma concentration of rilpivirine in the subject is maintained at a level of 12 ng / ml to 100 ng / ml for at least six months.

[0137] As used herein, the term "treatment of HIV infection" relates to the treatment of a subject infected with HIV. The term "treatment of HIV infection" also relates to the treatment of diseases associated with HIV infection (e.g., AIDS) or other conditions associated with HIV infection, such as thrombocytopenia, Kaposi's sarcoma, and infections of the central nervous system characterized by progressive demyelination, resulting in dementia and symptoms such as progressive dysarthria, ataxia, and disorientation, further symptoms associated with HIV infection (e.g., peripheral neuropathy, progressive generalized lymphadenopathy (PGL), and AIDS-related syndrome (ARC)).

[0138] As used herein, the term "prevention of HIV infection" relates to preventing or avoiding a subject (not infected with HIV) from becoming infected with HIV. The source of infection can be various HIV-containing materials, particularly HIV-containing bodily fluids, such as blood or semen, or another subject infected with HIV. Prevention of HIV infection relates to preventing the transmission of the virus from an HIV-containing material or an HIV-infected individual to an uninfected person, or to preventing the virus from entering the body of an uninfected person. Transmission of the HIV virus can be through any known cause of HIV transfer, such as sexual transmission or contact with the blood of an infected subject (e.g., medical staff providing care to an infected subject). HIV infection can also occur through contact with HIV-infected blood, for example, when handling blood samples or using blood transfusions. HIV infection can also be through contact with infected cells, for example, when performing laboratory experiments with HIV-infected cells.

[0139] The term "treatment of HIV infection" refers to a treatment that reduces the HIV viral load (expressed as the number of copies of viral RNA in a specific volume of serum). The more effective the treatment, the lower the viral load. Preferably, the viral load should be reduced to as low a level as possible, for example, less than about 200 copies / ml, particularly less than about 100 copies / ml, more particularly less than 50 copies / ml, and if possible, below the limit of viral detection. A reduction of viral load by one, two, or even three orders of magnitude (e.g., about 10 to about 10 2 or more, e.g., about 10 3A decrease in CD4 count (e.g., about 50, 100, 200, or more cells per μl) is an indicator of the effectiveness of treatment. Another parameter for measuring the effectiveness of HIV treatment is the CD4 count, which ranges from 500 to 1,500 cells per μl in normal adults. A decrease in CD4 count is an indicator of HIV infection, and a decrease below about 200 cells per μl can lead to the development of AIDS. An increase in CD4 count (e.g., about 50, 100, 200, or more cells per μl) is also an indicator of the effectiveness of anti-HIV treatment. In particular, the CD4 count should increase to a level greater than about 200 cells per μl, or greater than about 350 cells per μl. Viral load, CD4 count, or both can be used to diagnose the extent of HIV infection.

[0140] The term "treatment of HIV infection" and similar terms refer to treatment that reduces viral load, increases CD4 count, or both, as described above. The term "prevention of HIV infection" and similar terms refer to a situation in which the relative number of newly infected subjects is reduced in a population in contact with a source of HIV infection, such as HIV-containing material or HIV-infected subjects. Effective prevention can be measured, for example, by determining whether there is a reduction in the relative number of newly infected individuals in a mixed population of HIV-infected and uninfected individuals when comparing uninfected individuals treated with a pharmaceutical composition of the invention with untreated uninfected individuals. This reduction can be measured by statistical analysis of the number of infected and uninfected individuals in a given population over time.

[0141] In a second aspect, there is provided rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use in treating or preventing HIV infection in a subject, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension, and the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered to the subject by intramuscular or subcutaneous injection, and the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

[0142] It will be understood that all of the embodiments described herein with respect to the first aspect, such as those relating to rilpivirine in the first aspect of the invention, hyaluronidase in the first aspect of the invention, and the use of rilpivirine and hyaluronidase in the first aspect of the invention, apply equally, i.e., are disclosed herein in relation to this second aspect of the invention.

[0143] In a third aspect, a product is provided that contains rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase as a combined preparation for simultaneous or sequential use in the treatment or prevention of HIV infection by intramuscular or subcutaneous injection, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension, and the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

[0144] It will be understood that all of the embodiments described herein with respect to the first aspect, such as those relating to rilpivirine in the first aspect of the invention, hyaluronidase in the first aspect of the invention, and the use of rilpivirine and hyaluronidase in the first aspect of the invention, apply equally, i.e., are disclosed herein in relation to this third aspect of the invention.

[0145] In a fourth aspect, there is provided a kit of parts comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for simultaneous or sequential use in the treatment or prevention of HIV infection by intramuscular or subcutaneous injection, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension, and the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

[0146] It will be understood that all of the embodiments described herein with respect to the first aspect, such as those relating to rilpivirine in the first aspect of the invention, hyaluronidase in the first aspect of the invention, and the use of rilpivirine and hyaluronidase in the first aspect of the invention, apply equally, i.e., are disclosed herein in relation to this fourth aspect of the invention.

[0147] In a fifth aspect, there is provided rilpivirine or a pharmaceutically acceptable salt thereof in the form of a suspension of microparticles or nanoparticles for use in the treatment or prevention of HIV infection by intramuscular or subcutaneous injection, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is administered in combination with hyaluronidase administered by intramuscular or subcutaneous injection, and the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered intermittently at time intervals of from about 3 months to about 2 years.

[0148] It will be understood that all of the embodiments described herein with respect to the first aspect, such as the embodiments relating to rilpivirine in the first aspect of the invention, the hyaluronidase in the first aspect of the invention, and the use of rilpivirine and hyaluronidase in the first aspect of the invention, apply equally, i.e., are disclosed herein in relation to this fifth aspect of the invention.

[0149] In a sixth aspect, there is provided a use of rilpivirine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing HIV infection in a subject, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension and is administered in combination with hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered to the subject by intramuscular or subcutaneous injection, and the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

[0150] It will be understood that all of the embodiments described herein with respect to the first aspect, such as those relating to rilpivirine in the first aspect of the invention, hyaluronidase in the first aspect of the invention, and the use of rilpivirine and hyaluronidase in the first aspect of the invention, apply equally, i.e., are disclosed herein in relation to this sixth aspect of the invention.

[0151] In a seventh aspect, there is provided a combination comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension.

[0152] It will be understood that all of the embodiments described herein with respect to the first aspect, for example, the embodiments relating to rilpivirine in the first aspect of the invention and the hyaluronidase in the first aspect of the invention, apply equally, i.e., are also disclosed herein with respect to this seventh aspect of the invention.

[0153] In some embodiments there is provided a combination according to the seventh aspect of the invention for use in the treatment or prevention of HIV infection, wherein the combination is administered intermittently by intramuscular or subcutaneous injection at time intervals of from about 3 months to about 2 years.

[0154] In an eighth aspect, a kit of parts is provided comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension.

[0155] It will be understood that all of the embodiments described herein with respect to the first aspect, for example, the embodiments relating to rilpivirine in the first aspect of the invention and the hyaluronidase in the first aspect of the invention, apply equally, i.e., are disclosed herein in relation to this eighth aspect of the invention.

[0156] In a twelfth aspect, there is provided a method for treating or preventing HIV infection in a subject, the method comprising administering to the subject rilpivirine or a pharmaceutically acceptable salt thereof according to the ninth aspect of the invention in the form of microparticles or nanoparticles in a suspension, wherein the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v It has 90.

[0157] It will be understood that all of the embodiments described herein in relation to the eleventh aspect, e.g., embodiments relating to rilpivirine in the eleventh aspect of the invention, apply equally, i.e., are also disclosed herein in relation to this twelfth aspect of the invention.

[0158] In a thirteenth aspect, there is provided the use of rilpivirine or a pharmaceutically acceptable salt thereof according to the ninth aspect of the invention, i.e., rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in suspension, for the manufacture of a medicament for treating or preventing HIV infection in a subject, wherein the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v 90, the use is provided.

[0159] It will be understood that all of the embodiments described herein in relation to the eleventh aspect, e.g., embodiments relating to rilpivirine in the eleventh aspect of the invention, apply equally, i.e., are also disclosed herein in relation to this thirteenth aspect of the invention.

[0160] In one embodiment of the first to eighth aspects of the invention, the method or use or combination or product or kit-of-parts described herein is used in combination with one or more other active agents, particularly one or more other antiretroviral agents, particularly one or more other antiretroviral agents of another class, for example an antiretroviral agent of the INSTI class, such as cabotegravir. In one embodiment of the first to eighth aspects of the invention, the one or more other antiretroviral agents, for example cabotegravir, are administered as an intramuscular or subcutaneous injection, in particular as an injectable micro- or nanosuspension, at a time interval of from about 3 months to about 2 years. In one embodiment of the first through eighth aspects of the invention, the one or more other antiretroviral agents, e.g., cabotegravir, are administered at the same intermittent time intervals as the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase of the first through eighth aspects of the invention described herein, e.g., the rilpivirine or a pharmaceutically acceptable salt thereof, the hyaluronidase, and the other antiretroviral agent are administered intermittently at time intervals of about 3 months, or about 4 months, or about 5 months, or about 6 months, or about 7 months, or about 8 months, or about 10 months, or about 11 months, or about 1 year, or about 1 year to about 2 years. In one embodiment of the first through eighth aspects of the invention, the rilpivirine or a pharmaceutically acceptable salt thereof, the hyaluronidase, and the one or more other antiretroviral agents, e.g., cabotegravir, are administered simultaneously or sequentially by intramuscular or subcutaneous injection, particularly subcutaneous injection. In one embodiment of the first to eighth aspects of the invention, rilpivirine or a pharmaceutically acceptable salt thereof, hyaluronidase, and one or more other antiretroviral agents, such as cabotegravir, are administered simultaneously, particularly by subcutaneous injection. In one embodiment of the first to eighth aspects of the invention, rilpivirine or a pharmaceutically acceptable salt thereof, hyaluronidase, and one or more other antiretroviral agents, such as cabotegravir, are administered sequentially, particularly by subcutaneous injection. In one embodiment of the first to eighth aspects of the invention, hyaluronidase is administered first, followed by rilpivirine or a pharmaceutically acceptable salt thereof, and then cabotegravir is injected.In one embodiment of the first to eighth aspects of the present invention, hyaluronidase is administered first, followed by an injection of cabotegravir, followed by administration of rilpivirine or a pharmaceutically acceptable salt thereof.

[0161] In one embodiment of the eleventh to thirteenth aspects of the invention, the treatment / prophylaxis of the invention is used in combination with one or more other active agents, particularly one or more other antiretroviral agents, particularly one or more other antiretroviral agents of another class, for example an antiretroviral agent of the INSTI class, such as cabotegravir. In one embodiment of the eleventh to thirteenth aspects of the invention, the one or more other antiretroviral agents, for example cabotegravir, are administered as an intramuscular or subcutaneous injection, particularly as an injectable micro- or nanosuspension, at a time interval of about 3 months to about 2 years. In one embodiment of the eleventh to thirteenth aspects of the invention, the one or more other antiretroviral agents, e.g., cabotegravir, are administered at the same intermittent time intervals as rilpivirine or a pharmaceutically acceptable salt thereof described herein, e.g., rilpivirine or a pharmaceutically acceptable salt thereof and the other antiretroviral agent(s) are administered intermittently at time intervals of about 3 months, or about 4 months, or about 5 months, or about 6 months, or about 7 months, or about 8 months, or about 10 months, or about 11 months, or about 1 year, or about 1 year to about 2 years. In one embodiment of the eleventh to thirteenth aspects of the invention, rilpivirine or a pharmaceutically acceptable salt thereof and the one or more other antiretroviral agents, e.g., cabotegravir, are administered simultaneously or sequentially by intramuscular or subcutaneous injection, particularly subcutaneous injection. In one embodiment of the eleventh to thirteenth aspects of the invention, rilpivirine or a pharmaceutically acceptable salt thereof and one or more other antiretroviral agents, such as cabotegravir, are administered simultaneously, particularly by subcutaneous injection. In one embodiment of the eleventh to thirteenth aspects of the invention, rilpivirine or a pharmaceutically acceptable salt thereof and one or more other antiretroviral agents, such as cabotegravir, are administered sequentially, particularly by subcutaneous injection. In one embodiment of the eleventh to thirteenth aspects of the invention, rilpivirine or a pharmaceutically acceptable salt thereof is administered first, followed by the injection of cabotegravir. In one embodiment of the eleventh to thirteenth aspects of the invention, cabotegravir is injected first, followed by the administration of rilpivirine or a pharmaceutically acceptable salt thereof.

[0162] For the avoidance of doubt, the pharmaceutical composition according to the tenth aspect of the present invention may also be used for the treatment or prevention according to the eleventh to thirteenth aspects of the present invention.

[0163] General definition The term "comprising" encompasses "including" as well as "consisting," e.g., a composition "comprising" X may consist only of X, or may include something additional, e.g., X+Y. As used herein, the term "comprising" also encompasses "consisting essentially of," e.g., a composition "comprising" X may consist of X plus any other ingredients that do not materially affect the essential characteristics of the composition.

[0164] The term "about" in relation to a numerical value Y is arbitrary and means, for example, Y±10%.

[0165] If the time interval is expressed as a specified number of months, the time interval extends from a given numbered day in a given month to the same numbered day in the corresponding month the specified number of months later. If the same numbered day does not exist in the corresponding month the specified number of months later, the time interval extends into the next month for the same number of days as if the same numbered day existed in the corresponding month the specified number of months later.

[0166] If the time interval is expressed as a number of years, the interval extends from a given date in a given year to the same date in the specified number of years later. If the same date does not exist in the specified number of years later, the interval extends for the same number of days as if the same-numbered day existed in the specified number of months later. In other words, if the time interval begins on February 29 of a given year but ends in a year that does not have February 29, the interval ends on March 1 of that year.

[0167] The term "about" in connection with such a definition means that the time interval may end on a date that is ±10% of the time interval.

[0168] In one embodiment, the time interval may begin up to 7 days before or after the start of the time interval and end up to 7 days before or after the end of the time interval.

[0169] All references cited herein are incorporated by reference in their entirety.

[0170] The present invention will now be described with reference to the following examples. For the avoidance of doubt, these examples are not intended to limit the scope of the present invention. Modifications may be made within the scope and spirit of the present invention. [Example]

[0171] Example 1 - Administration of Rilpivirine with Hyaluronidase In this example, the plasma kinetics after administration of a suspension of rilpivirine are compared to the plasma kinetics after sequential administration of first a hyaluronidase solution and then a rilpivirine suspension.

[0172] Preparation of Rilpivirine and Hyaluronidase Compositions (a) Rilpivirine suspension 300 mg / mL suspension of rilpivirine (D v A 3.380 mL fill of 50 (approximately 200 nm) was prepared in a 4R glass vial using the following excipients: ●Poloxamer 338 (50mg / ml) Glucose monohydrate (19.25mg / ml) Sodium dihydrogen phosphate monohydrate (2.00 mg / ml) ●Citric acid monohydrate (1.00mg / ml) Sodium hydroxide (0.866 mg / ml) ●Water for injection (appropriate amount 3mL)

[0173] The suspension was prepared as follows. The buffer solution was prepared by dissolving citric acid monohydrate, sodium dihydrogen phosphate monohydrate, sodium hydroxide, and glucose monohydrate in water for injection in a stainless steel container. Poloxamer 338 was added to the buffer solution and mixed until dissolved. The first fraction of the poloxamer 338 buffer solution was passed sequentially through a prefilter and two serially connected sterile filters into a sterile stainless steel container. The sterile drug substance (micronized and irradiated) was aseptically dispersed in the sterile solution via a charged isolator. The remaining fraction of the poloxamer 338 buffer solution was passed sequentially through a prefilter and two serially connected sterile filters into a milling container to produce a suspension concentrate. During and after the addition of the drug substance, the suspension concentrate was mixed to wet and disperse the drug substance.

[0174] Pulverization of suspension concentrates The suspension concentrate in the grinding vessel was aseptically milled by circulating it through a sterile stainless steel grinding chamber using sterile zirconia beads as the grinding media. During the grinding process, the suspension was circulated between the grinding chamber and the grinding vessel by a peristaltic pump until the target particle size was achieved.

[0175] Dilute the suspension concentrate to the final concentration. The suspension concentrate in the holding vessel was diluted with water for injection, which was sterile filtered through a prefilter and two serially connected sterile filters, through a grinding chamber and a 70 μm stainless steel filter into the vessel. After the final dilution, the headspace of the vessel was blanketed with nitrogen and the suspension was mixed until homogeneous.

[0176] Final suspension holding and filling While mixing, the suspension was aseptically transferred from the holding vessel to a time / pressure (t / p) dosing vessel from which the suspension was filled into vials, which were flushed with nitrogen, stoppered, and capped with aluminum seals having flip-off buttons.

[0177] (b) Hyaluronidase (rHuPH20) solution Prepare rHuPH20 concentrate (1 x 10) by adding 10 mM histidine, 300 mM sorbitol, 1 mg / mL methionine, pH 5.6, 0.04% polysorbate 20 buffer. 6 A solution of rHuPH20 was prepared by diluting rHuPH20 to 10,000 U / mL.

[0178] The solution was sterile filtered and provided in 1 mL aliquots of 10,000 U / mL filled into 2R sterile glass vials.

[0179] procedure Six minipigs weighing 20-25 kg at the start of the study were used. The minipigs were fasted overnight before administration. Three minipigs received 0.19 mL of hyaluronidase solution (10,000 U / mL) followed by 900 mg / 3 mL of rilpivirine nanosuspension subcutaneously in the lumbar region at the same injection site (treatment group A). ​​Three minipigs received 900 mg / 3 mL of control rilpivirine suspension subcutaneously in the lumbar region (treatment group B - control). The injection volume was 3 mL of rilpivirine suspension in both treatment groups.

[0180] Method - Continuous administration 1. Remove the flip cap from the rHuPH20 solution vial and wipe with an isopropyl alcohol wipe. Allow to dry. Attach an 18G transfer needle to a 1 mL syringe. 2. Draw 0.35 mL into the syringe. 3. Prepare the syringe and set the liquid level in the syringe to 0.25 mL. 4. Remove the transfer needle and attach the syringe cap to the 1 mL syringe. 5. Mix the rilpivirine by shaking the container horizontally 30 times (2 back and forth arm movements) over approximately 25 cm within approximately 10 seconds. Ensure thorough mixing / complete resuspension. 6. Remove the flip cap from the rilpivirine vial and wipe with an isopropyl alcohol wipe. Allow to dry. 7. Attach an 18G transfer needle to a 5mL syringe. 8. Invert the vial and draw >3.2 mL (or as much as can be removed from the vial) into a 5 mL syringe. Injecting 1-2 mL of air will facilitate the aspiration. 9. Remove the needle and attach the syringe cap to the 5 mL syringe. 10. Invert the syringe and wait 5 minutes for the bubbles to settle. 11. Attach the winged infusion set to the 1 mL syringe of rHuPH20. Invert the syringe and remove air so that liquid forms at the tip of the needle. (There should be 0.19 mL of rHuPH20 in the line.) 12. Insert the winged infusion set into the subcutaneous tissue at the target injection site by pinching the skin and inserting the needle at a 30-45 degree angle. 13. Release the knob. 14. Remove the rHuPH20 syringe from the infusion set, keeping the needle subcutaneous. While priming the rilpivirine syringe, keep the luer end (open end) facing upward to prevent fluid from exiting the infusion line. It is recommended that you prime this syringe while the technician is inserting the rHuPH20 infusion line. 15. Remove the syringe cap from the 5 mL syringe containing rilpivirine. Remove the air and set the dose to 3.2 mL. 16. Attach the syringe filled with rilpivirine to the open end of the infusion set. 17. Infuse steadily over 1 minute until the syringe plunger bottoms out (this leaves approximately 0.19 mL of rilpivirine in the infusion line). 18. Remove and discard the winged infusion set. 19. Document any site leakage.

[0181] Photographing the injection site • The injection site was visually assessed for protrusion.

[0182] Blood sampling ● 2 mL blood samples were collected from the jugular vein of all minipigs at time intervals over the following 2160 hours. Blood samples were placed on EDTA. Within 1 hour of blood sampling, samples were centrifuged at approximately 1900 x g for ±10 minutes at 5°C to allow plasma separation. Plasma was immediately transferred to a second tube and stored in a freezer within 1 hour after the start of centrifugation. Plasma samples were individually analyzed by a validated LC-MS / MS method.

[0183] Pharmacokinetic data analysis ● Using non-compartmental pharmacokinetic analysis (individual C p The pharmacokinetic profile of plasma samples was evaluated using the mean plasma concentrations and PK parameters (C max , T max , t 1 / 2 and AUC values) were measured, and the results are shown in Table 1.

[0184] Results and Discussion

[0185] [Table 2] a: Median (minimum - maximum) b: N=2, control 0005 not included in calculation of summary statistics.

[0186] Table 1 and Figure 1 demonstrate that administration of the nanosuspension of hyaluronidase and rilpivirine according to the present invention, as well as administration of the nanosuspension of rilpivirine alone, results in plasma rilpivirine levels over a period of at least three months. Surprisingly, the long-term sustained release profile of rilpivirine is maintained when administered with hyaluronidase.

[0187] Example 2 - Effect of sequential and combined administration of rilpivirine and hyaluronidase over 6 months after a single dose This example compares plasma kinetics over a six-month period for three conditions: (i) administration of rilpivirine suspension (control); (ii) sequential administration of first hyaluronidase solution and then rilpivirine suspension; and (iii) combined administration of hyaluronidase solution and rilpivirine suspension.

[0188] Preparation of Rilpivirine and Hyaluronidase Compositions (a) Rilpivirine suspension A suspension of rilpivirine was prepared as described in Example 1.

[0189] (b) Hyaluronidase (rHuPH20) solution A solution of hyaluronidase was prepared as described in Example 1.

[0190] procedure Nine minipigs weighing 17 to 21 kg at the start of the study were used. The minipigs were fasted overnight before administration and anesthetized with propofol. Three minipigs received 0.44 mL of hyaluronidase solution (10,000 U / mL) followed by 1818 mg / 6.06 mL of rilpivirine nanosuspension subcutaneously at the same injection site in the lumbar region (treatment group A - sequential). Three minipigs received 1816 mg / 6.5 mL of a mixed hyaluronidase solution (10,000 U / mL) + rilpivirine suspension subcutaneously in the lumbar region (treatment group B - mixed). Three minipigs received 1830 mg / 6.1 mL of a control rilpivirine suspension subcutaneously in the lumbar region (treatment group C - control). If necessary, injection sites were sealed using Vetbond 3M surgical sealant to limit leakage.

[0191] Methods—Rilpivirine control A control rilpivirine suspension was prepared and administered in the following manner. 1. Mix the rilpivirine by shaking the container horizontally 30 times (2 back and forth arm movements) over approximately 25 cm within approximately 10 seconds. Ensure thorough mixing / complete resuspension. 2. Remove the flip cap from the rilpivirine vial and wipe it with an isopropyl alcohol wipe. Allow to dry. 3. Repeat steps 1-2 with the second vial of rilpivirine. If there is a low draw or an unexpected amount of air / sedimentation after drawing, it may be necessary to prepare a third vial to ensure the appropriate dose level can be loaded into the syringe. 4. Attach an 18G transfer needle to a 10mL syringe. 5. Invert the vial and draw >3.2 mL (or as much as you can get out of the vial) into a 10 mL syringe. Injecting 1-2 mL of air will facilitate the aspiration. Repeat step 5 with the second vial so that approximately 6.5 mL of drug product is in the 10 mL syringe. Important: See note (in step 3) about preparing a third vial in case of small volume withdrawals. 6. Remove the needle and attach the syringe cap to the 10 mL syringe. 7. Invert the syringe and wait 5 minutes for the bubbles to settle. 8. Remove the syringe cap and invert the syringe to remove any air. 9. Attach the winged infusion set. 10. After filling the infusion set line, set the dose to 6.1 mL until liquid forms at the tip of the needle (0.44 mL of non-deliverable / dead space exists within the infusion set). 11. Insert the winged infusion set into the subcutaneous tissue at the target injection site by pinching the skin and inserting the needle at a 30-45 degree angle. 12. Release the knob. 13. Inject at a steady rate over 2 minutes until the syringe plunger bottoms out. 14. Remove and discard the winged infusion set. 15. Document any site leakage.

[0192] Methods - (i) Continuous administration Sequential administration of the hyaluronidase solution followed by the rilpivirine suspension was performed according to the following method. 1. Remove the flip cap from the rHuPH20 solution vial and wipe with an isopropyl alcohol wipe. Swirl the vial. Allow the vial stopper to dry. Attach an 18G transfer needle to a 1 mL syringe. 2. Draw 0.70 mL into the syringe. 3. Prepare the syringe and set the liquid level in the syringe to 0.60 mL. 4. Remove the transfer needle and attach the syringe cap to the 1 mL syringe. 5. Mix the rilpivirine by shaking the container horizontally 30 times (2 back and forth arm movements) over approximately 25 cm within approximately 10 seconds. Ensure thorough mixing / complete resuspension. 6. Remove the flip cap from the rilpivirine vial and wipe with an isopropyl alcohol wipe. Allow to dry. 7. Repeat steps 5-6 with the second vial of rilpivirine. If there is a low draw or an unexpected amount of air / sedimentation after drawing, it may be necessary to prepare a third vial to ensure the appropriate dose level can be loaded into the syringe. 8. Attach an 18G transfer needle to a 10mL syringe. 9. Invert the vial and draw >3.2 mL (or as much as can be removed from the vial) into a 10 mL syringe. Injecting 1-2 mL of air will facilitate the aspiration. 10. Repeat step 9 with the second vial so that approximately 6.5 mL of drug product is in the 10 mL syringe. Important: See note (in step 7) about preparing a third vial in case of small volume withdrawals. 11. Remove the needle and attach the syringe cap to the 10 mL syringe. 12. Invert the syringe and wait 5 minutes for the bubbles to settle. 13. Attach the winged infusion set to the 1 mL syringe of rHuPH20. Invert the syringe and remove air so that liquid forms at the tip of the needle. (There should be 0.44 mL of rHuPH20 in the line.) 14. Insert the winged infusion set into the subcutaneous tissue at the target injection site by pinching the skin and inserting the needle at a 30-45 degree angle. 15. Release the knob. 16. Remove the rHuPH20 syringe from the infusion set, keeping the needle subcutaneous. While priming the rilpivirine syringe, keep the open end facing upward to prevent fluid from exiting the infusion line. It is recommended that you prime this syringe while the technician is inserting the rHuPH20 infusion line. 17. Remove the syringe cap from the 10 mL syringe containing rilpivirine. Remove the air and set the dose to approximately 6.5 mL. 18. Attach the syringe filled with rilpivirine to the open end of the infusion set. 19. Infuse at a steady rate over 1 minute until the syringe plunger bottoms out (this leaves approximately 0.44 mL of rilpivirine in the infusion line). 20. Remove and discard the winged infusion set. 21. Document any site leakage.

[0193] Method-(ii) Mixed administration The mixed administration of the hyaluronidase solution and the rilpivirine suspension was carried out in the following manner. 1. Remove the flip cap from the rHuPH20 solution vial and wipe with an isopropyl alcohol wipe. Allow to dry. Attach an 18G transfer needle to a 1 mL syringe. 2. Draw 0.40 mL into the syringe. 3. Prepare the syringe and set the liquid level in the syringe to 0.35 mL. 4. Remove the transfer needle and attach the syringe cap to the 1 mL syringe. 5. Mix the rilpivirine by shaking the container horizontally 30 times (2 back and forth arm movements) over approximately 25 cm within approximately 10 seconds. Ensure thorough mixing / complete resuspension. 6. Remove the flip cap from the rilpivirine vial and wipe with an isopropyl alcohol wipe. Allow to dry. 7. Remove the syringe cap from the 1 mL PH20 filled syringe and attach a 25G needle. 8. Prepare the syringe so that liquid forms at the needle tip and set the syringe to approximately 0.25 mL. 9. Insert the 25G needle / rHuPH20 solution syringe into the vial so that the needle is submerged in the liquid. 10. Transfer 0.25 mL of rHuPH20 solution (2500 U) to a rilpivirine vial. 11. Gently shake the vial. 12. Repeat steps 1-10 to prepare a second vial of rilpivirine with rHuPH20. If there is a low draw or an unexpected amount of air / sedimentation after drawing, it may be necessary to prepare a third vial to ensure the appropriate dose level can be loaded into the syringe. 13. Attach an 18G transfer needle to a 10mL syringe. 14. Invert the vial and draw >3.4 mL (or as much as you can get out of the vial) into a 10 mL syringe. Injecting 1-2 mL of air will facilitate the aspiration. 15. Repeat step 14 with the second prepared vial so that approximately 7.0 mL of drug product is in the 10 mL syringe. Important: See note (in step 12) about preparing a third vial in case of small volume withdrawals. 16. Remove the needle and attach the syringe cap to the 10 mL syringe. 17. Invert the syringe and wait 5 minutes for the bubbles to settle. 18. Remove the syringe cap, remove the air so that the droplets are on the needle, and set the volume to 6.5 mL after priming. 19. Attach a winged infusion set to a 10 mL syringe. Invert the syringe and remove air so that liquid forms at the tip of the needle. 20. Insert the winged infusion set into the subcutaneous tissue at the target injection site by pinching the skin and inserting the needle at a 30-45 degree angle. 21. Infuse steadily over 1 minute until the syringe plunger bottoms out (this leaves approximately 0.44 mL of rilpivirine in the infusion line). 22. Remove and discard the winged infusion set. 23. Document site leakage.

[0194] Photographing the injection site • The injection site was visually assessed for protrusion.

[0195] Blood sampling Two-mL blood samples were collected from the jugular of all minipigs at timed intervals over the following six months. Blood samples were placed on EDTA. Within one hour of blood sampling, samples were centrifuged at approximately 1900 x g for ±10 minutes at 5°C to allow plasma separation. Plasma was immediately transferred to a second tube and stored in a freezer within one hour after the start of centrifugation. Plasma samples were individually analyzed by a validated LC-MS / MS method.

[0196] Pharmacokinetic data analysis ● Using non-compartmental pharmacokinetic analysis (individual C p The PK profile of plasma samples was evaluated using the mean plasma concentrations and PK parameters (C max and AUC values) were measured, and the results are shown in Table 2.

[0197] Results and Discussion The PK parameters after a single subcutaneous administration of 6 mL of rilpivirine nanosuspension with and without rHuPH20 solution (sequential and mixed administration) are shown in Table 2.

[0198] [Table 3] a Exclude outlier minipigs (C of 563 ng / mL at 7 hours after administration) max (having).

[0199] Table 2 and Figure 2 demonstrate that both sequential and combined administration of hyaluronidase and rilpivirine nanosuspension according to the present invention, as well as administration of rilpivirine nanosuspension alone, resulted in release from the injection site with measurable plasma rilpivirine levels over a period of at least six months. Surprisingly, the long-term extended release profile of rilpivirine is maintained both when administered sequentially with hyaluronidase and after combined administration.

[0200] Example 3 - Dissolution test with varying particle size This example compares the dissolution profiles of three rilpivirine suspensions, each with a different particle size.

[0201] Preparation of rilpivirine suspension and particle size determination A rilpivirine suspension was prepared according to the method described in Example 1 (Suspension 1). Two additional suspensions with the same composition as Example 1 but different particle sizes were prepared by blending and milling as described below (Suspensions 2 and 3).

[0202] Preparation of Suspensions 2 and 3 1.586.62 g of water for injection was added to a 2 L glass beaker with a magnetic stir bar. 2. The correct amounts of citric acid monohydrate, sodium dihydrogen phosphate monohydrate, and sodium hydroxide were added and stirred until dissolved. 3. The correct amount of Poloxamer 338 and glucose monohydrate were added and stirred until dissolved. 4. The diluent was filtered through a 0.22 μm filter and the beaker was rinsed with the remaining 100 mL of water for injection and filtered. 5. Rilpivirine nanoparticles were added and stirred until a homogeneous suspension was obtained. 6. 500 mL of the suspension was transferred to a sterile beaker and placed in a double-walled cooled glass beaker containing a magnetic stir bar. 7. Milling begins in the Netzsch Labstar and continues until the target particle size distribution is reached. For suspension 2, the milling time was approximately 180 minutes. For suspension 3, the milling time was approximately 35 minutes. 8. The particle size distribution was measured during grinding. 9. Each suspension was diluted to 300 mg / mL.

[0203] Particle size distribution measurement The volumetric particle size distribution of the rilpivirine suspension was determined by wet dispersion laser diffraction using a Malvern Mastersizer3000 laser diffraction (Malvern Instruments) and a HydroMV wet dispersion module.

[0204] The particle sizes of the three rilpivirine suspensions were as defined in Table 3.

[0205] [Table 4]

[0206] In vitro dissolution assay The three rilpivirine suspensions were dissolved in water using a paddle apparatus (USP Type 2, European Pharmacopoeia, Japanese Pharmacopoeia) at 50 rpm in 900 mL of 6.0% (w / v) polysorbate 20 in 0.05 M sodium phosphate buffer (pH 7.4) at 5.0 ± 0.5°C. 64.98 mg (= 0.06 mL × 1.083 g / mL (theoretical density of the suspension)) ± 5% homogeneous suspension of rilpivirine (corresponding to 18 ± 0.9 mg of rilpivirine) was added.

[0207] Measurement of the amount of rilpivirine present in the dissolved samples was based on a gradient ultra-high performance liquid chromatography (UHPLC) method with UV detection at 280 nm. The results are shown in Figure 3.

[0208] Results and Discussion FIG. 3 shows that administration of rilpivirine in the form of microparticles or nanoparticles having particle sizes larger than those shown in Table 3 surprisingly reduced, ie, flattened, the dissolution profile of rilpivirine.

[0209] Example 4 - Further dissolution studies with varying particle size This example compares the dissolution profiles of five rilpivirine suspensions, each with a different particle size.

[0210] Preparation of rilpivirine suspension and particle size determination Five suspensions of rilpivirine were prepared according to a method corresponding to that described for suspensions 2 and 3 in Example 3. The volumetric particle size distribution of the rilpivirine microparticles or nanoparticles in the suspensions was determined according to a method corresponding to that specified in Example 3.

[0211] [Table 5]

[0212] In vitro dissolution assay The five rilpivirine suspensions were dissolved in water according to the method described in Example 3.

[0213] Results and Discussion As Figure 4 and Table 4 demonstrate, as the particle size of rilpivirine in the form of microparticles or nanoparticles increases, the dissolution profile of rilpivirine decreases, ie, flattens.

[0214] The following numbered clauses are also set forth herein: 1. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use in treating or preventing HIV infection in a subject, comprising: wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension; Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered to a subject by intramuscular or subcutaneous injection; Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at intervals of about 3 months to about 2 years. 2. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 1, wherein the hyaluronidase is, for example, a recombinant human hyaluronidase (e.g., rHuPH20 enzyme) comprising the amino acid sequence of SEQ ID NO: 1. 3. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the time interval is from about 3 months to about 1 year. 4. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 3, wherein the time interval is about 3 months to about 6 months. 5. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 3, wherein the time interval is from about 6 months to about 1 year, and in particular the time interval is about 6 months. 6. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered simultaneously or sequentially. 7. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the microparticles or nanoparticles have a surface modifier adsorbed to their surface. 8. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 7, wherein the surface modifier is a poloxamer. 9. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 8, wherein the poloxamer is poloxamer 338. 10. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the average effective particle size of the microparticles or nanoparticles is less than about 1 μm. 11. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 10, wherein the average effective particle size of the microparticles or nanoparticles is less than about 500 nm. 12. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 11, wherein the average effective particle size of the microparticles or nanoparticles is from about 100 nm to about 300 nm. 13. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 12, wherein the average effective particle size of the microparticles or nanoparticles is from about 150 nm to about 250 nm. 14. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 13, wherein the average effective particle size of the microparticles or nanoparticles is from about 180 nm to about 220 nm. 15. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered sequentially. 16. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered in separate pharmaceutical compositions. 17. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to Clause 16, wherein the pharmaceutical composition comprising hyaluronidase is a solution, and the concentration of the hyaluronidase in the solution is about 50 to about 10,000 U / mL, particularly about 2,000 U / mL. 18. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of clauses 1 to 14, wherein the rilpivirine or a pharmaceutically acceptable salt thereof and the hyaluronidase are administered as a combined pharmaceutical composition. 19. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered by subcutaneous injection. 20. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which the rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 21. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the treatment or prevention of HIV infection is treatment of HIV infection. 22. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 21, wherein each dose of rilpivirine or a pharmaceutically acceptable salt thereof comprises from about 2700 mg to about 5400 mg of rilpivirine or a pharmaceutically acceptable salt thereof, in particular from about 2700 mg to about 4500 mg of rilpivirine or a pharmaceutically acceptable salt thereof. 23. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the HIV infection is HIV type 1 (HIV-1) infection. 24. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the subject is a human. 25. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of the preceding clauses, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine. 26. A combination for use in the treatment or prevention of HIV infection, comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension; The combination is administered intermittently by subcutaneous or intramuscular injection at time intervals of about 3 months to about 2 years. 27. The combination for use according to clause 26, wherein the hyaluronidase is, for example, a recombinant human hyaluronidase (e.g., rHuPH20) comprising the amino acid sequence of SEQ ID NO: 1. 28. A combination for use according to clause 26 or 27, wherein the time interval is from about 3 months to about 1 year. 29. A combination for use according to clause 28, wherein the time interval is from about 3 months to about 6 months. 30. A combination for use according to clause 28, wherein the time interval is between about 6 months and about 1 year, in particular the time interval is about 6 months. 31. The combination for use according to any one of clauses 26 to 30, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered simultaneously or sequentially. 32. A combination for use according to any one of clauses 26 to 31, wherein the microparticles or nanoparticles have a surface modifier adsorbed on their surface. 33. The combination for use according to clause 32, wherein the surface modifier is a poloxamer. 34. The composition according to clause 33, wherein the poloxamer is poloxamer 338. 35. A combination for use according to any one of clauses 26 to 34, wherein the average effective particle size of the microparticles or nanoparticles is less than about 1 μm. 36. The combination for use according to clause 35, wherein the average effective particle size of the microparticles or nanoparticles is less than about 500 nm. 37. The combination for use according to clause 36, wherein the average effective particle size of the microparticles or nanoparticles is from about 100 nm to about 300 nm. 38. The combination for use according to clause 37, wherein the average effective particle size of the microparticles or nanoparticles is from about 150 nm to about 250 nm. 39. The combination for use according to clause 38, wherein the average effective particle size of the microparticles or nanoparticles is from about 180 nm to about 220 nm. 40. The combination for use according to any one of clauses 26 to 39, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered sequentially. 41. The combination for use according to any one of clauses 26 to 40, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered in separate pharmaceutical compositions. 42. The combination for use according to clause 41, wherein the pharmaceutical composition comprising hyaluronidase is a solution, and the concentration of hyaluronidase in the solution is about 50 to about 10,000 U / mL, particularly about 2,000 U / mL. 43. The combination for use according to any one of clauses 26 to 39, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered as a combined pharmaceutical composition. 44. The combination for use according to any one of clauses 26 to 43, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered by subcutaneous injection. 45. A combination for use according to any one of clauses 26 to 44, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 46. ​​The combination for use according to any one of clauses 26 to 45, wherein the treatment or prevention of HIV infection is treatment of HIV infection. 47. The combination for use according to clause 46, wherein each administration of rilpivirine or a pharmaceutically acceptable salt thereof comprises from about 2700 mg to about 5400 mg of rilpivirine or a pharmaceutically acceptable salt thereof, in particular from about 2700 mg to about 4500 mg of rilpivirine or a pharmaceutically acceptable salt thereof. 48. The combination for use according to any one of clauses 26 to 47, wherein the HIV infection is an HIV type 1 (HIV-1) infection. 49. A combination for use according to any one of clauses 26 to 48, wherein the subject is a human. 50. A combination for use according to any one of clauses 26 to 49, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine. 51. A product containing rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase as a combined preparation for simultaneous or sequential use in the treatment or prevention of HIV infection by subcutaneous or intramuscular injection, comprising: wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension; A product in which rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at intervals of about 3 months to about 2 years. 52. The product for simultaneous or sequential use described in clause 51, wherein the hyaluronidase is a recombinant human hyaluronidase (e.g., rHuPH20), e.g., comprising the amino acid sequence of SEQ ID NO: 1. 53. A product for simultaneous or sequential use according to any one of clauses 51 to 52, wherein the time interval is from about 3 months to about 1 year. 54. A product for simultaneous or sequential use according to clause 53, wherein the time interval is from about 3 months to about 6 months. 55. A product for simultaneous or sequential use according to clause 53, wherein the time interval is from about 6 months to about 1 year, in particular the time interval is about 6 months. 56. A product for simultaneous or sequential use according to any one of clauses 51 to 55, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered sequentially. 57. A product for simultaneous or sequential use according to any one of clauses 51 to 56, wherein the microparticles or nanoparticles have a surface modifier adsorbed on their surface. 58. The product for simultaneous or sequential use according to clause 57, wherein the surface modifier is a poloxamer. 59. A product for simultaneous or sequential use according to clause 58, wherein the poloxamer is poloxamer 338. 60. A product for simultaneous or sequential use according to any one of clauses 51 to 59, wherein the average effective particle size of the microparticles or nanoparticles is less than about 1 μm. 61. A product for simultaneous or sequential use according to clause 60, wherein the average effective particle size of the microparticles or nanoparticles is less than about 500 nm. 62. A product for simultaneous or sequential use according to clause 61, wherein the average effective particle size of the microparticles or nanoparticles is from about 100 nm to about 300 nm. 63. The product for simultaneous or sequential use according to clause 62, wherein the average effective particle size of the microparticles or nanoparticles is from about 150 nm to about 250 nm. 64. The product for simultaneous or sequential use described in clause 63, wherein the average effective particle size of the microparticles or nanoparticles is from about 180 nm to about 220 nm. 65. A product for simultaneous or sequential use according to any one of clauses 51 to 64, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered sequentially by subcutaneous injection. 66. A product for simultaneous or sequential use according to any one of clauses 51 to 65, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered in separate pharmaceutical compositions. 67. The product for simultaneous or sequential use according to clause 66, wherein the pharmaceutical composition comprising hyaluronidase is a solution, and the concentration of hyaluronidase in the solution is about 50 to about 10,000 U / mL, particularly about 2,000 U / mL. 68. A product for simultaneous or sequential use according to any one of clauses 51 to 64, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered as a combined pharmaceutical composition. 69. A product for simultaneous or sequential use according to any one of clauses 51 to 68, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered by subcutaneous injection. 70. A product for simultaneous or sequential use according to any one of clauses 51 to 69, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 71. A product for simultaneous or sequential use according to any one of clauses 51 to 70, wherein the treatment or prevention of HIV infection is treatment of HIV infection. 72. A product for simultaneous or sequential use according to clause 71, wherein each dose of rilpivirine or a pharmaceutically acceptable salt thereof contains from about 2700 mg to about 5400 mg of rilpivirine or a pharmaceutically acceptable salt thereof, in particular from about 2700 mg to about 4500 mg of rilpivirine or a pharmaceutically acceptable salt thereof. 73. A product for simultaneous or sequential use according to any one of clauses 51 to 72, wherein the HIV infection is HIV type 1 (HIV-1) infection. 74. A product for simultaneous or sequential use according to any one of clauses 51 to 73, wherein the subject is a human. 75. A product for simultaneous or sequential use according to any one of clauses 51 to 74, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine. 76. A kit of parts comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for simultaneous or sequential use in the treatment or prevention of HIV infection by subcutaneous or intramuscular injection, comprising: wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension; A kit of parts in which rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at intervals of about 3 months to about 2 years. 77. The kit of parts for simultaneous or sequential use according to clause 76, wherein the hyaluronidase is, for example, a recombinant human hyaluronidase (e.g., rHuPH20) comprising the amino acid sequence of SEQ ID NO: 1. 78. A kit of parts for simultaneous or sequential use according to clause 76 or 77, wherein the time interval is from about 3 months to about 1 year. 79. A kit of parts for simultaneous or sequential use according to Clause 78, wherein the time interval is from about 3 months to about 6 months. 80. A kit of parts for simultaneous or successive use according to clause 78, wherein the time interval is from about 6 months to about 1 year, in particular the time interval is about 6 months. 81. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 80, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered sequentially. 82. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 81, wherein the microparticles or nanoparticles have a surface modifier adsorbed on their surface. 83. A kit of parts for simultaneous or sequential use according to clause 82, wherein the surface modifier is a poloxamer. 84. A kit of parts for simultaneous or sequential use according to clause 83, wherein the poloxamer is poloxamer 338. 85. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 84, wherein the average effective particle size of the microparticles or nanoparticles is less than about 1 μm. 86. A kit of parts for simultaneous or sequential use according to clause 85, wherein the average effective particle size of the microparticles or nanoparticles is less than about 500 nm. 87. A kit of parts for simultaneous or sequential use according to clause 86, wherein the average effective particle size of the microparticles or nanoparticles is from about 100 nm to about 300 nm. 88. A kit of parts for simultaneous or sequential use according to clause 87, wherein the average effective particle size of the microparticles or nanoparticles is from about 150 nm to about 250 nm. 89. A kit of parts for simultaneous or sequential use according to clause 88, wherein the average effective particle size of the microparticles or nanoparticles is from about 180 nm to about 220 nm. 90. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 89, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered sequentially by subcutaneous injection. 91. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 90, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered in separate pharmaceutical compositions. 92. The kit of parts for simultaneous or sequential use according to Clause 91, wherein the pharmaceutical composition containing hyaluronidase is a solution, and the concentration of hyaluronidase in the solution is about 50 to about 10,000 U / mL, particularly about 2,000 U / mL. 93. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 89, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered as a combined pharmaceutical composition. 94. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 93, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered by subcutaneous injection. 95. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 94, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 96. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 95, wherein the treatment or prevention of HIV infection is treatment of HIV infection. 97. A kit of parts for simultaneous or sequential use according to clause 96, wherein each dose of rilpivirine or a pharmaceutically acceptable salt thereof contains from about 2700 mg to about 5400 mg of rilpivirine or a pharmaceutically acceptable salt thereof, in particular from about 2700 mg to about 4500 mg of rilpivirine or a pharmaceutically acceptable salt thereof. 98. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 97, wherein the HIV infection is HIV type 1 (HIV-1) infection. 99. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 98, wherein the subject is a human. 100. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 99, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine. 101. Rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension for use in the treatment or prevention of HIV infection by subcutaneous or intramuscular injection, Rilpivirine or a pharmaceutically acceptable salt thereof is administered in combination with hyaluronidase administered by subcutaneous or intramuscular injection; Rilpivirine or a pharmaceutically acceptable salt thereof, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at intervals of about 3 months to about 2 years. 102. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 101, wherein the hyaluronidase is, for example, a recombinant human hyaluronidase (e.g., rHuPH20) comprising the amino acid sequence of SEQ ID NO: 1. 103. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 101 or 102, wherein the time interval is from about 3 months to about 1 year. 104. Rilpivirine or a pharmaceutically acceptable salt thereof, as used according to clause 103, wherein the time interval is from about 3 months to about 6 months, in particular the time interval is about 6 months. 105. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 103, wherein the time interval is from about 6 months to about 1 year. 106. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 105, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered simultaneously or sequentially. 107. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 106, wherein the microparticles or nanoparticles have a surface modifier adsorbed to their surface. 108. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 107, wherein the surface modifier is a poloxamer. 109. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 108, wherein the poloxamer is poloxamer 338. 110. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 109, wherein the average effective particle size of the microparticles or nanoparticles is less than about 1 μm. 111. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 110, wherein the average effective particle size of the microparticles or nanoparticles is less than about 500 nm. 112. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 111, wherein the average effective particle size of the microparticles or nanoparticles is from about 100 nm to about 300 nm. 113. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 112, wherein the average effective particle size of the microparticles or nanoparticles is from about 150 nm to about 250 nm. 114. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 113, wherein the average effective particle size of the microparticles or nanoparticles is from about 180 nm to about 220 nm. 115. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 114, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered sequentially. 116. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 115, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered in separate pharmaceutical compositions. 117. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to Clause 116, wherein the pharmaceutical composition comprising hyaluronidase is a solution, and the concentration of hyaluronidase in the solution is about 50 to about 10,000 U / mL, particularly about 2,000 U / mL. 118. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 114, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered as a combined pharmaceutical composition. 119. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 118, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered by subcutaneous injection. 120. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 119, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 121. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 120, wherein the treatment or prevention of HIV infection is treatment of HIV infection. 122. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 121, wherein each administration of rilpivirine or a pharmaceutically acceptable salt thereof contains from about 2700 mg to about 5400 mg of rilpivirine or a pharmaceutically acceptable salt thereof, in particular from about 2700 mg to about 4500 mg of rilpivirine or a pharmaceutically acceptable salt thereof. 123. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 122, wherein the HIV infection is HIV type 1 (HIV-1) infection. 124. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 123, wherein the subject is a human. 125. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 124, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine. 126. Use of rilpivirine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing HIV infection in a subject, comprising: rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension and is administered in combination with hyaluronidase; Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered to a subject by intramuscular or subcutaneous injection; Use in which rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered intermittently at intervals of about 3 months to about 2 years. 127. The use of clause 126, wherein the hyaluronidase is a recombinant human hyaluronidase (e.g., rHuPH20), e.g., comprising the amino acid sequence of SEQ ID NO: 1. 128. The use according to clause 126 or 127, wherein the time interval is from about 3 months to about 1 year. 129. The use according to Clause 128, wherein the time interval is from about 3 months to about 6 months. 130. Use according to clause 129, in which the time interval is from about 6 months to about 1 year, in particular the time interval is about 6 months. 131. The use according to any one of clauses 126 to 130, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered simultaneously or sequentially. 132. Use according to any one of clauses 126 to 131, in which the microparticles or nanoparticles have a surface modifier adsorbed on their surface. 133. The use according to clause 132, wherein the surface modifier is a poloxamer. 134. The use according to clause 133, wherein the poloxamer is poloxamer 338. 135. The use according to any one of clauses 126 to 134, wherein the average effective particle size of the microparticles or nanoparticles is less than about 1 μm. 136. The use according to clause 135, wherein the average effective particle size of the microparticles or nanoparticles is less than about 500 nm. 137. The use according to clause 136, wherein the average effective particle size of the microparticles or nanoparticles is from about 100 nm to about 300 nm. 138. The use according to clause 137, wherein the average effective particle size of the microparticles or nanoparticles is from about 150 nm to about 250 nm. 139. The use according to clause 138, wherein the average effective particle size of the microparticles or nanoparticles is from about 180 nm to about 220 nm. 140. The use according to any one of clauses 126 to 139, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered sequentially. 141. The use according to any one of clauses 126 to 140, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered in separate pharmaceutical compositions. 142. The use according to clause 141, wherein the pharmaceutical composition comprising hyaluronidase is a solution, and the concentration of hyaluronidase in the solution is about 50 to about 10,000 U / mL, particularly about 2,000 U / mL. 143. The use according to any one of clauses 126 to 139, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered as a combined pharmaceutical composition. 144. The use according to any one of clauses 126 to 143, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are administered by subcutaneous injection. 145. The use according to any one of clauses 126 to 144, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 146. The use according to any one of clauses 126 to 145, wherein the use is for the manufacture of a medicament for treating HIV infection in a subject. 147. The use according to clause 146, wherein each administration of rilpivirine or a pharmaceutically acceptable salt thereof contains from about 2700 mg to about 5400 mg of rilpivirine or a pharmaceutically acceptable salt thereof, in particular from about 2700 mg to about 4500 mg of rilpivirine or a pharmaceutically acceptable salt thereof. 148. The use according to any one of clauses 126 to 147, wherein the HIV infection is HIV type 1 (HIV-1) infection. 149. The use of any one of clauses 126 to 148, wherein the subject is a human. 150. The use according to any one of clauses 126 to 149, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine. 151. A combination comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension. 152. The combination of clause 151, wherein the hyaluronidase is, for example, a recombinant human hyaluronidase (e.g., rHuPH20) comprising the amino acid sequence of SEQ ID NO:1. 153. The combination of any one of clauses 151 to 152, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are formulated for simultaneous or sequential administration. 154. The combination of any one of clauses 151-153, wherein the microparticles or nanoparticles have a surface modifier adsorbed to their surface. 155. The combination according to clause 154, wherein the surface modifier is a poloxamer. 156. The combination according to clause 155, wherein the poloxamer is poloxamer 338. 157. The combination of any one of clauses 151-156, wherein the average effective particle size of the microparticles or nanoparticles is less than about 1 μm. 158. The combination of clause 157, wherein the average effective particle size of the microparticles or nanoparticles is less than about 500 nm. 159. The combination of clause 158, wherein the average effective particle size of the microparticles or nanoparticles is from about 100 nm to about 300 nm. 160. The combination of clause 159, wherein the average effective particle size of the microparticles or nanoparticles is from about 150 nm to about 250 nm. 161. The combination of clause 160, wherein the average effective particle size of the microparticles or nanoparticles is from about 180 nm to about 220 nm. 162. The combination according to any one of clauses 151 to 161, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are formulated for sequential administration. 163. The combination according to any one of clauses 151 to 162, wherein rilpivirine or a pharmaceutically acceptable salt thereof and / or hyaluronidase are formulated for administration in separate pharmaceutical compositions. 164. The combination according to article 163, wherein the pharmaceutical composition comprising hyaluronidase is a solution, and the concentration of hyaluronidase in the solution is from about 50 to about 10,000 U / mL, in particular about 2,000 U / mL. 165. The combination of any one of clauses 151 to 161, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are formulated for administration as a combined pharmaceutical composition. 166. The combination of any one of clauses 151 to 165, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are formulated for administration by subcutaneous injection. 167. The combination of any one of clauses 151 to 166, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 168. The combination according to any one of clauses 151 to 167, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine. 169. A kit-of-parts comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension. 170. The kit of parts of clause 169, wherein the hyaluronidase is, for example, a recombinant human hyaluronidase (e.g., rHuPH20) comprising the amino acid sequence of SEQ ID NO:1. 171. The kit of parts according to clause 169 or 170, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are formulated for simultaneous or sequential administration. 172. A kit of parts according to any one of clauses 169 to 171, wherein the microparticles or nanoparticles have a surface modifier adsorbed on their surface. 173. The kit of parts according to clause 172, wherein the surface modifier is a poloxamer. 174. The kit of parts according to clause 173, wherein the poloxamer is poloxamer 338. 175. A kit of parts according to any one of clauses 169 to 174, wherein the average effective particle size of the microparticles or nanoparticles is less than about 1 μm. 176. The kit of parts of clause 175, wherein the average effective particle size of the microparticles or nanoparticles is less than about 500 nm. 177. The kit of parts of clause 176, wherein the microparticles or nanoparticles have an average effective particle size of about 100 nm to about 300 nm. 178. The kit of parts of clause 177, wherein the microparticles or nanoparticles have an average effective particle size of about 150 nm to about 250 nm. 179. The kit of parts of clause 178, wherein the microparticles or nanoparticles have an average effective particle size of about 180 nm to about 220 nm. 180. The kit of parts according to any one of clauses 169 to 179, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are formulated for sequential administration. 181. The kit of parts according to any one of clauses 169 to 180, wherein rilpivirine or a pharmaceutically acceptable salt thereof and / or hyaluronidase are formulated for administration in separate pharmaceutical compositions. 182. The kit of parts according to Clause 181, wherein the pharmaceutical composition comprising hyaluronidase is a solution, and the concentration of hyaluronidase in the solution is about 50 to about 10,000 U / mL, particularly about 2,000 U / mL. 183. The kit of parts according to any one of clauses 169 to 179, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are formulated for administration as a combined pharmaceutical composition. 184. The kit of parts according to any one of clauses 169 to 183, wherein rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase are formulated for administration by subcutaneous injection. 185. The kit of parts according to any one of clauses 169 to 184, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 186. The kit of parts according to any one of clauses 169 to 185, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine. 187. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of clauses 1 to 9 and 15 to 25, when not subject to any one of clauses 10 to 14, wherein the microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm. 188. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to Clause 187, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, and more preferably about 2 μm to about 3 μm. 189. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to Clause 187, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. 190. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to clause 189, wherein the microparticles or nanoparticles have an average effective particle size of about 2.5 μm. 191. Microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v 90, comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of clauses 1 to 9 and 15 to 25 when not subject to any one of clauses 10 to 14. 192. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90. Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to Clause 191. 193. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90, Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to Clause 192. 194. Microparticles or nanoparticles have a D of about 5.5 μm. v 90, Rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to Clause 193. 195. Microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm and a D of about 1.8 μm to about 7 μm. v 90, comprising rilpivirine or a pharmaceutically acceptable salt thereof and hyaluronidase for use according to any one of clauses 1 to 9 and 15 to 25 when not subject to any one of clauses 10 to 14. 196. A combination for use according to any one of clauses 26 to 34 and 40 to 50, when not subject to any one of clauses 35 to 39, wherein the microparticles or nanoparticles have an average effective particle size of from about 0.2 μm to about 3 μm. 197. The combination for use according to clause 196, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, more preferably about 2 μm to about 3 μm. 198. The combination for use according to clause 196, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. 199. A combination for use according to clause 198, wherein the microparticles or nanoparticles have an average effective particle size of about 2.5 μm. 200. Microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v 90. A combination for use according to any one of clauses 26 to 34 and 40 to 50 when not subject to any one of clauses 35 to 39. 201. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90. A combination for use according to clause 200. 202. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90. A combination for use according to clause 201. 203. Microparticles or nanoparticles have a D of about 5.5 μm. v 90. A combination for use according to clause 202. 204. Microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm and a D of about 1.8 μm to about 7 μm. v 90. A combination for use according to any one of clauses 26 to 34 and 40 to 50 when not subject to any one of clauses 35 to 39. 205. A product for simultaneous or sequential use according to any one of clauses 51 to 59 and 65 to 75, when not subject to any one of clauses 60 to 64, in which the microparticles or nanoparticles have an average effective particle size of from about 0.2 μm to about 3 μm. 206. A product for simultaneous or sequential use according to clause 205, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, more preferably about 2 μm to about 3 μm. 207. A product for simultaneous or sequential use according to Clause 205, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. 208. A product for simultaneous or sequential use according to Clause 207, wherein the microparticles or nanoparticles have an average effective particle size of about 2.5 μm. 209. Microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v 90, products for simultaneous or sequential use as defined in any one of clauses 51 to 59 and 65 to 75 when not subject to any one of clauses 60 to 64. 210. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90. A product for simultaneous or sequential use as described in clause 209. 211. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90. A product for simultaneous or sequential use as described in clause 210. 212. Microparticles or nanoparticles have a D of about 5.5 μm. v 90. A product for simultaneous or sequential use as described in clause 211. 213. Microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm and a D of about 1.8 μm to about 7 μm. v 90, products for simultaneous or sequential use as defined in any one of clauses 51 to 59 and 65 to 75 when not subject to any one of clauses 60 to 64. 214. A kit of parts for simultaneous or sequential use according to any one of clauses 76 to 84 and 90 to 100, when not subject to any one of clauses 85 to 89, in which the microparticles or nanoparticles have an average effective particle size of from about 0.2 μm to about 3 μm. 215. A kit of parts for simultaneous or sequential use according to clause 214, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, more preferably about 2 μm to about 3 μm. 216. A kit of parts for simultaneous or sequential use according to Clause 214, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. 217. A kit of parts for simultaneous or sequential use according to Clause 216, wherein the microparticles or nanoparticles have an average effective particle size of about 2.5 μm. 218. Microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v 90, a kit of parts for simultaneous or sequential use according to any one of clauses 76 to 84 and 90 to 100 when not subject to any one of clauses 85 to 89. 219. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90. A kit of parts for simultaneous or sequential use as described in clause 218. 220. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90. A kit of parts for simultaneous or sequential use as described in clause 219. 221. Microparticles or nanoparticles have a D of about 5.5 μm. v 90. A kit of parts for simultaneous or sequential use according to clause 210. 222. Microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm and a D of about 1.8 μm to about 7 μm. v 90, a kit of parts for simultaneous or sequential use according to any one of clauses 76 to 84 and 90 to 100 when not subject to any one of clauses 85 to 89. 223. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 109 and 115 to 125 when not subject to any one of clauses 110 to 114, in which the microparticles or nanoparticles have an average effective particle size of from about 0.2 μm to about 3 μm. 224. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to Clause 223, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, more preferably about 2 μm to about 3 μm. 225. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to Clause 223, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. 226. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 225, wherein the microparticles or nanoparticles have an average effective particle size of about 2.5 μm. 227. Microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v 90, rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 109 and 115 to 125 when not subject to any one of clauses 110 to 114. 228. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90, Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 227. 229. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90, Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 228. 230. Microparticles or nanoparticles have a D of about 5.5 μm. v 90, Rilpivirine or a pharmaceutically acceptable salt thereof for use according to Clause 229. 231. Microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm and a D of about 1.8 μm to about 7 μm. v 90, rilpivirine or a pharmaceutically acceptable salt thereof for use according to any one of clauses 101 to 109 and 115 to 125 when not subject to any one of clauses 110 to 114. 232. The use according to any one of clauses 126 to 134 and 140 to 150, when not subject to any one of clauses 135 to 139, wherein the microparticles or nanoparticles have an average effective particle size of from about 0.2 μm to about 3 μm. 233. The use according to clause 232, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, more preferably about 2 μm to about 3 μm. 234. The use according to Clause 232, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. 235. The use according to clause 234, wherein the microparticles or nanoparticles have an average effective particle size of about 2.5 μm. 236. Microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v 90, the use according to any one of clauses 126 to 134 and 140 to 150 when not subject to any one of clauses 135 to 139. 237. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90. The use according to clause 236. 238. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90. The use according to clause 237. 239. Microparticles or nanoparticles have a D of about 5.5 μm. v 90. The use according to clause 238. 240. Microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm and a D of about 1.8 μm to about 7 μm. v 90, the use according to any one of clauses 126 to 134 and 140 to 150 when not subject to any one of clauses 135 to 139. 241. The combination of any one of clauses 151-156 and 162-169, when not subject to any one of clauses 157-161, wherein the microparticles or nanoparticles have an average effective particle size of from about 0.2 μm to about 3 μm. 242. The combination according to clause 241, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, more preferably about 2 μm to about 3 μm. 243. The combination of clause 241, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. 244. The combination according to clause 243, wherein the microparticles or nanoparticles have an average effective particle size of about 2.5 μm. 245. Microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v90, a combination according to any one of clauses 151 to 156 and 162 to 168 when not subject to any one of clauses 157 to 161. 246. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90. The combination according to clause 245. 247. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90. The combination according to clause 246. 248. Microparticles or nanoparticles have a D of about 5.5 μm. v 90. The combination according to clause 247. 249. Microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm and a D of about 1.8 μm to about 7 μm. v 90, a combination according to any one of clauses 151 to 156 and 162 to 168 when not subject to any one of clauses 157 to 161. 250. A kit of parts according to any one of clauses 169-174 and 180-186 when not subject to any one of clauses 175-179, wherein the microparticles or nanoparticles have an average effective particle size of from about 0.2 μm to about 3 μm. 251. The kit of parts according to Clause 250, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, more preferably about 2 μm to about 3 μm. 252. The kit of parts of clause 250, wherein the microparticles or nanoparticles have an average effective particle size of about 1 μm to about 2.5 μm. 253. The kit of parts according to Clause 252, wherein the microparticles or nanoparticles have an average effective particle size of about 2.5 μm. 254. Microparticles or nanoparticles have a D of about 2 μm to about 7 μm. v 90, a kit of parts as described in any one of clauses 169 to 174 and 180 to 86 when not subject to any one of clauses 175 to 179. 255. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90. A kit of parts as described in clause 254. 256. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90. The kit of parts described in clause 255. 257. Microparticles or nanoparticles have a D of about 5.5 μm. v 90. The kit of parts described in clause 256. 258. Microparticles or nanoparticles have an average effective particle size of about 0.2 μm to about 3 μm and a D of about 1.8 μm to about 7 μm. v 90, a kit of parts as described in any one of clauses 169 to 174 and 180 to 186 when not subject to any one of clauses 175 to 179. 259. Rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles in a suspension, wherein the microparticles or nanoparticles have a D of about 1 μm to about 10 μm. v 90, or a pharmaceutically acceptable salt thereof. 260. Microparticles or nanoparticles have a D of about 1 μm to about 7 μm, preferably about 2 μm to about 7 μm. v 90, or a pharmaceutically acceptable salt thereof, according to Clause 259. 261. Microparticles or nanoparticles have a D of about 3 μm to about 6 μm. v 90, or a pharmaceutically acceptable salt thereof, according to Clause 260. 262. Microparticles or nanoparticles have a D of about 3 μm to about 5.5 μm. v 90, or a pharmaceutically acceptable salt thereof, according to Clause 261. 263. Microparticles or nanoparticles have a D of about 1.8 μm to about 7 μm. v 90 and the average effective particle size (D v 50) Rilpivirine or a pharmaceutically acceptable salt thereof according to Article 259. 264. D v 264. Rilpivirine or a pharmaceutically acceptable salt thereof according to clause 262 or clause 263, wherein 90 is about 5.5 μm. 265. Rilpivirine or a pharmaceutically acceptable salt thereof according to clause 263 or clause 264, having an average effective particle size of about 2.5 μm. 266. Rilpivirine or a pharmaceutically acceptable salt thereof according to any one of clauses 259 to 265, wherein the microparticles or nanoparticles have a surface modifier adsorbed on their surface. 267. Rilpivirine or a pharmaceutically acceptable salt thereof according to Clause 266, wherein the surface modifier is a poloxamer. 268. Rilpivirine or a pharmaceutically acceptable salt thereof according to clause 267, wherein the poloxamer is poloxamer 338. 269. Rilpivirine or a pharmaceutically acceptable salt thereof according to any one of clauses 259 to 268, wherein the suspension comprises a pharmaceutically acceptable aqueous carrier in which rilpivirine or a pharmaceutically acceptable salt thereof is suspended. 270. Rilpivirine or a pharmaceutically acceptable salt thereof according to any one of clauses 259 to 269, wherein the rilpivirine or a pharmaceutically acceptable salt thereof is rilpivirine (i.e., rilpivirine free base). 271. A pharmaceutical composition comprising rilpivirine or a pharmaceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension according to any one of clauses 259-270. 272. The pharmaceutical composition according to clause 271, formulated for administration by subcutaneous or intramuscular injection. 273. The pharmaceutical composition according to clause 271, formulated for administration by subcutaneous injection. 274. Rilpivirine or a pharmaceutically acceptable salt thereof according to any one of clauses 259 to 270 for use in the treatment or prevention of HIV infection in a subject. 275. A method for treating or preventing HIV infection in a subject, the method comprising administering to the subject rilpivirine or a pharmaceutically acceptable salt thereof as defined in any one of clauses 259 to 270. 276. Use of rilpivirine or a pharmaceutically acceptable salt thereof according to any one of clauses 259 to 270 for the manufacture of a medicament for treating or preventing HIV infection in a subject. 277. Rilpivirine or a pharmaceutically acceptable salt thereof for use according to clause 274, the method according to clause 275, or the use according to clause 276, wherein rilpivirine or a pharmaceutically acceptable salt thereof is administered to the subject at time intervals of about 3 months to about 2 years. 278. Rilpivirine or a pharmaceutically acceptable salt thereof for use, method, or use according to clause 277, wherein the time interval is from about 3 months to about 6 months. 279. Rilpivirine or a pharmaceutically acceptable salt thereof for use, method, or use according to clause 277, wherein the time interval is from about 6 months to about 2 years. 280. Rilpivirine or a pharmaceutically acceptable salt thereof for use, method or use according to clause 279, wherein the time interval is from about 6 months to about 1 year, in particular about 6 months. 281. Rilpivirine or a pharmaceutically acceptable salt thereof for use, method or use according to any one of clauses 274 to 280, wherein rilpivirine or a pharmaceutically acceptable salt thereof is administered to the subject by subcutaneous or intramuscular injection. 282. Rilpivirine or a pharmaceutically acceptable salt thereof for use, method, or use according to clause 281, wherein rilpivirine or a pharmaceutically acceptable salt thereof is administered to the subject by subcutaneous injection. 283. Rilpivirine or a pharmaceutically acceptable salt thereof for use, method, or use according to any one of clauses 274 to 282, wherein the treatment or prevention of HIV infection is treatment of HIV infection. 284. Rilpivirine or a pharmaceutically acceptable salt thereof for use, method, or use according to clause 283, wherein each administration of rilpivirine or a pharmaceutically acceptable salt thereof contains from about 2700 mg to about 5400 mg of rilpivirine or a pharmaceutically acceptable salt thereof. 285. Rilpivirine or a pharmaceutically acceptable salt thereof, method, or use for use according to any one of clauses 274 to 284, wherein the HIV infection is HIV type 1 (HIV-1) infection. 286. Rilpivirine or a pharmaceutically acceptable salt thereof for use, method, or use according to any one of clauses 274 to 285, wherein the subject is a human.

Claims

1. 1. A pharmaceutical composition comprising rilpivirine or a pharma- ceutical acceptable salt thereof for use in a method for the treatment or prevention of HIV infection in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of rilpivirine or a pharma- ceutical acceptable salt thereof in the form of microparticles or nanoparticles in a suspension by intramuscular or subcutaneous injection; The rilpivirine or a pharma- ceutically acceptable salt thereof is administered in combination with hyaluronidase administered by intramuscular or subcutaneous injection; The pharmaceutical composition, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof and the hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

2. The pharmaceutical composition of claim 1, wherein the hyaluronidase is a recombinant human hyaluronidase (e.g., rHuPH20) comprising, for example, the amino acid sequence of SEQ ID NO:

1.

3. the time interval is from about 3 months to about 1 year; 3. The pharmaceutical composition according to claim 1 or 2, optionally wherein the time interval is from about 3 months to about 6 months, or wherein the time interval is from about 6 months to about 1 year, preferably wherein the time interval is about 6 months.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase are administered simultaneously or sequentially.

5. 5. The pharmaceutical composition according to any one of claims 1 to 4, wherein said microparticles or nanoparticles have a surface modifier adsorbed on their surface, optionally said surface modifier being a poloxamer, preferably said poloxamer is poloxamer 338.

6. 6. The pharmaceutical composition of any one of claims 1 to 5, wherein the average effective particle size of the microparticles or nanoparticles is (i) less than about 1 μm, or (ii) less than about 500 nm, or (iii) from about 100 nm to about 300 nm, or (iv) from about 150 nm to about 250 nm, or (v) from about 180 nm to about 220 nm.

7. 6. The pharmaceutical composition of any one of claims 1 to 5, wherein the microparticles or nanoparticles have an average effective particle size of: (i) about 0.2 μm to about 3 μm, or (ii) about 1 μm to about 3 μm, preferably about 1.5 μm to about 3 μm, more preferably about 2 μm to about 3 μm, or (iii) about 1 μm to about 2.5 μm, or (iv) about 2.5 μm.

8. The microparticles or nanoparticles have a D of (i) about 2 μm to about 7 μm, or (ii) about 3 μm to about 6 μm, or (iii) about 3 μm to about 5.5 μm, or (iv) about 5.5 μm. v 90. The pharmaceutical composition according to any one of claims 1 to 5.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase are administered sequentially.

10. The pharmaceutical composition of any one of claims 1 to 9, wherein rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase are administered in separate pharmaceutical compositions.

11. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprising the hyaluronidase is a solution and the concentration of the hyaluronidase in the solution is about 50 to about 10,000 U / mL, preferably about 2,000 U / mL.

12. The pharmaceutical composition according to any one of claims 1 to 8, wherein rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase are administered as a combined pharmaceutical composition.

13. The pharmaceutical composition of any one of claims 1 to 12, wherein rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase are administered by subcutaneous injection.

14. 14. The pharmaceutical composition of any one of claims 1 to 13, wherein the suspension comprises a pharma- ceutically acceptable aqueous carrier in which rilpivirine or a pharma- ceutically acceptable salt thereof is suspended.

15. 15. The pharmaceutical composition according to any one of claims 1 to 14, wherein the method is a method for treating an HIV infection, the subject is a human, and optionally the treatment or prevention of an HIV infection is treatment of an HIV infection.

16. 16. The pharmaceutical composition of claim 15, wherein each administration of rilpivirine or a pharma- ceutically acceptable salt thereof comprises from about 2700 mg to about 5400 mg of rilpivirine or a pharma- ceutically acceptable salt thereof, preferably from about 2700 mg to about 4500 mg of rilpivirine or a pharma- ceutically acceptable salt thereof.

17. The pharmaceutical composition according to any one of claims 1 to 16, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof is rilpivirine.

18. A product containing rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase as a combined preparation for simultaneous or sequential use in the treatment or prevention of HIV infection by intramuscular or subcutaneous injection, comprising: the rilpivirine or a pharma- ceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension; The product, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof and the hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

19. A kit of parts comprising rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase for simultaneous or sequential use in the treatment or prevention of HIV infection by intramuscular or subcutaneous injection, the rilpivirine or a pharma- ceutically acceptable salt thereof is in the form of microparticles or nanoparticles in suspension; The kit of parts, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof and the hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

20. 1. Use of rilpivirine or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing HIV infection in a subject, comprising: the rilpivirine or a pharma- ceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension and is administered in combination with hyaluronidase; the rilpivirine or a pharma- ceutically acceptable salt thereof and the hyaluronidase are administered to the subject by intramuscular or subcutaneous injection; The use, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof and the hyaluronidase are administered intermittently at time intervals of about 3 months to about 2 years.

21. A combination comprising rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension.

22. A kit-of-parts comprising rilpivirine or a pharma- ceutically acceptable salt thereof and hyaluronidase, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof is in the form of microparticles or nanoparticles in a suspension.

23. Rilpivirine or a pharma- ceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension, said microparticles or nanoparticles having a D of about 1 μm to about 10 μm. v 90, or a pharmacy acceptable salt thereof.

24. 24. Rilpivirine or a pharma- ceutically acceptable salt thereof according to claim 23, wherein the microparticles or nanoparticles have (i) a Dv 90 of about 1 μm to about 7 μm, preferably about 2 μm to about 7 μm, or (ii) a Dv 90 of about 3 μm to about 6 μm, preferably about 3 μm to about 5.5 μm, preferably 5.5 μm, or (iii) a Dv 90 of about 1.8 μm to about 7 μm, and an average effective particle size of about 0.2 μm to about 3 μm, preferably the average effective particle size is about 2.5 μm.

25. (i) the microparticles or nanoparticles have a surface modifier adsorbed on their surface, optionally wherein the surface modifier is a poloxamer, preferably the poloxamer is poloxamer 338; and / or (ii) the suspension comprises a pharma- ceutically acceptable aqueous carrier in which rilpivirine or a pharma- ceutically acceptable salt thereof is suspended; and / or (iii) The method of claim 23 or 24, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof is rilpivirine.

26. A pharmaceutical composition comprising rilpivirine or a pharma- ceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension according to any one of claims 23 to 25.

27. 27. The pharmaceutical composition of claim 26, formulated for administration by subcutaneous or intramuscular injection.

28. Use of rilpivirine or a pharma- ceutically acceptable salt thereof according to any one of claims 23 to 25 for the manufacture of a medicament for treating or preventing HIV infection in a subject.

29. 29. The use of claim 28, wherein rilpivirine or a pharma- ceutically acceptable salt thereof is administered to the subject at time intervals of about 3 months to about 2 years, optionally, (i) said time interval is about 3 months to about 6 months, or (ii) said time interval is about 6 months to about 1 year, preferably said time interval is about 6 months.

30. 30. The use according to claim 28 or 29, wherein rilpivirine or a pharma- ceutically acceptable salt thereof is administered to the subject by subcutaneous or intramuscular injection.

31. The use according to any one of claims 28 to 30, wherein the treatment or prevention of an HIV infection is treatment of an HIV infection, and the subject is a human, optionally wherein the treatment or prevention of an HIV infection is treatment of an HIV infection.

32. 32. The use according to claim 31, wherein each administration of rilpivirine or a pharma- ceutically acceptable salt thereof comprises from about 2700 mg to about 5400 mg of rilpivirine or a pharma- ceutically acceptable salt thereof, preferably from about 2700 mg to about 4500 mg of rilpivirine or a pharma- ceutically acceptable salt thereof.

33. A pharmaceutical composition comprising a therapeutically effective amount of rilpivirine or a pharma- ceutically acceptable salt thereof in the form of microparticles or nanoparticles in a suspension, wherein the amount of rilpivirine or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition is from about 1800 mg to about 4500 mg, in particular from about 2700 mg to about 4500 mg, or from about 1800 mg to about 3600 mg, in particular from about 2700 mg to about 3600 mg.

34. The pharmaceutical composition of claim 33, wherein the microparticles or nanoparticles have a surface modifier adsorbed on their surface, optionally wherein the surface modifier is a poloxamer, preferably the poloxamer is poloxamer 338.

35. The pharmaceutical composition of claim 33 or 34, wherein the suspension comprises a pharma- ceutically acceptable aqueous carrier in which rilpivirine or a pharma- ceutically acceptable salt thereof is suspended, and the rilpivirine or a pharma- ceutically acceptable salt thereof is rilpivirine.

36. The pharmaceutical composition of any one of claims 33 to 35, wherein the pharmaceutical composition is formulated for administration by subcutaneous injection or intramuscular injection, optionally formulated for administration by intramuscular injection.

37. A pharmaceutical composition according to any one of claims 33 to 36, for use in treating or preventing HIV infection in a subject.

38. The pharmaceutical composition of claim 37, wherein the rilpivirine or a pharma- ceutically acceptable salt thereof is used at time intervals of about 3 months to about 2 years, and optionally, (i) the time interval is about 3 months to about 6 months, or (ii) the time interval is about 6 months to about 1 year, or (iii) the time interval is about 6 months.